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Abstract 
INTERACTIONS BETWEEN PATHOGENIC BACTERIA 
AND MACROPHAGES IN ORAL PATHOLOGY 
 
Louise Alicia Belfield 
Macrophages play a fundamental role in driving both inflammatory and immunosuppressive 
conditions of the oral mucosa. Periodontitis, a chronic inflammatory condition affecting the 
supporting structures of the teeth, is widely prevalent, affecting a large proportion of the 
global population, and has been linked to the development of systemic inflammatory 
diseases. Oral squamous cell carcinoma (OSCC) is placed sixth in the WHO rankings of 
cancer incidence worldwide, and despite continuing research into underlying mechanisms, 
incidence is on the rise. Aberrant macrophage function has been implicated in the 
pathogenesis of both diseases.  On recruitment to sites of inflammation, macrophages 
become polarised within a spectrum of effector phenotypes depending on the factors they 
encounter in their microenvironment. These cells are highly plastic and continuously adapt 
their effector functions in response to locally derived stimuli.  Mechanisms have been 
developed by pathogenic bacteria and transformed host tissues to exploit this plasticity and 
manipulate macrophage phenotype to facilitate disease progression. However, this plasticity 
is also available for therapeutic manipulation. The main objectives of this study therefore 
were to investigate the interactions between macrophages and pathogenic stimuli in the 
context of oral pathology with a view to identifying novel therapeutic targets.  
Firstly, a reproducible model of M1 and M2 macrophage polarisation using the THP-1 cell 
line was established to study their interactions with pathogenic stimuli. Treating the cells with 
combinations of PMA plus IFNγ or IL-4 for 24 hours led to two distinct populations of cells:  
PMA + IFNγ treated cells expressed higher levels of pro-inflammatory cytokines TNFα, IL-1β 
and IL-6, but lower levels of IL-10 and TGF-β, characteristic of M1 macrophages. PMA + IL-
4 treated cells expressed lower levels of  TNFα, IL-1β and IL-6 and higher levels of IL-10 
and TGF-β, characteristic of M2 macrophages.  
As P. gingivalis LPS is present in the developing periodontal lesion, cytokine expression 
from macrophages exposed to LPS during polarisation was investigated. Exposure of 
macrophages to 1 µg/ml Pg LPS during polarisation led to a statistically significant  down-
regulation of inflammatory cytokines TNFα (10-, 4- and 5.5 –fold decrease in PMA, M1 and 
M2 cells, respectively) and IL-1β (1.9-, 2.0- and 1.5 –fold decrease in PMA, M1 and M2 
macrophages, respectively) in response to subsequent stimulation with LPS. IL-6 production 
was not affected. The same pattern of cytokine down regulation was observed regardless of 
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LPS species used, and in most cases, at a lower dose of 1 ng/ml LPS during polarisation. 
Finally, as macrophages recruited to the tumour environment will be influenced by tumour-
secreted factors, the response of macrophages to LPS stimulation in the presence of OSCC 
conditioned media was examined. Contrariwise to polarisation with LPS, exposure of 
macrophages to OSCC produced factors during polarisation led to an amplification of  IL-1β 
(13.8-, 2.3- and 8.8 –fold increase in PMA, M1 and M2 cells, respectively),  and IL-6 (16.8-, 
17.3- and 44.9 –fold increase in PMA, M1 and M2 cells, respectively), but not TNFα in 
response to LPS. Counter intuitively, these findings suggest that LPS manipulation of 
macrophage polarisation might result in a more M2 –like population of cells, whereas OSCC 
produced factors may result in a more M1- like population of cells. Viewed therapeutically, 
one short, single exposure of macrophages to LPS would up-regulate pro-inflammatory 
cytokines, whereas prolonged or chronic exposure would lead to the down-regulation of pro-
inflammatory cytokines, therefore, LPS as a therapeutic modulator of macrophage function 
in an immunosuppressive (M2) environment to an inflammatory environment (M1) would 
only be viable as a single dose. For chronic inflammatory disease however, a repasted or 
prolonged exposure of macrophages to LPS skews macrophages to display a more M2-like 
cytokine profile and could dampen down detrimental pro-inflammatory cytokine production. 
The continued study of macrophage/ P. gingivalis interactions may shed light on pathogenic 
mechanisms not only in oral pathological conditions, but in a range of diseases.  
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Chapter 1  General introduction 
 
Overview of oral mucosal immunity 
The primary function of the oral mucosal immune system is to selectively and discriminately 
tolerate oral microbiota and food antigens, whilst retaining the capacity to launch an immune 
response to pathogenic challenge. The mouth contains a plethora of site-specific bacteria 
(over 750 distinct species) 1 and the teeth are the most densely populated tissues, with 
approximately 80% of the  bacterial species inhabiting the dental plaque 2. In comparison, 
the mucosal tissue is sparsely populated. Some oral bacteria are pathogenic, for example 
Streptococcus mutans, implicated in dental caries3, and Porphyromonas gingivalis, a 
periodontal pathogen 4, however, most oral bacteria present are commensal; they benefit 
from inhabiting the oral environment, but do not adversely affect the host. The key role of 
the oral mucosal immune system is thus to discriminate between the pathogenic and 
commensal microbiota/food antigens.  
The innate immune response in the oral mucosa 
As part of the innate, mechanical barrier to pathogens, saliva has numerous protective and 
anti-microbial functions. It performs a physical ‘sloughing’ action on the epithelial cells, 
removing potentially infected cells from contact with the underlying immune cells. Saliva also 
contains secretory immunoglobulin A (sIgA) produced by activated B cells (plasma cells) 
distributed throughout the mucosa 5, which can inhibit binding of bacteria to the mucosal 
surface, thus limiting colonisation 6. In addition, antimicrobial peptides in the saliva play a 
role in mucosal immunity. Human Beta defensin 3 (HBD3) may have protective effects 
against P. gingivalis invasion by binding to antigens on the bacterial cell surface, such as 
hemaglutinin B (HaB), an extracellular adhesin, inhibiting the binding to the host cells 7. 
Salivary lysozyme elicits its antibacterial effects by lysing peptidoglycan (a bacterial cell wall 
component), and activating bacterial autolytic enzymes 8. To reinforce the mechanical barrier 
between foreign antigens and the host’s immune system, oral squamous epithelial cells 
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secrete mucins and a layer of anti-microbial peptides such as α- and β-defensins 9,10. Thus; 
secretory factors contribute to innate immune defence against pathogens in the oral cavity.  
 
The mechanism by which a pathogen initiates an immune response is dependant both on 
the cell it encounters, and the nature of the pathogen. Typically, professional antigen 
presenting cells (such as macrophages and dendritic cells) are the first point of contact 
between antigens and cells of the innate immune system. Highly conserved molecular 
patterns on a bacterial cell wall, such as lipopolysaccharide (LPS), can activate antigen 
presenting cells (APCs) and initiate an immune response. LPS binding protein (LBP) in the 
serum binds to the LPS and forms a complex with CD14 (a co-stimulatory molecule), MD2 
and toll-like receptor (TLR) 4 11 on the surface of the APC. Ligation of TLR 4 activates a 
downstream signalling cascade 12, resulting in the activation of transcription factors and the 
expression of pro-inflammatory cytokines (such as TNFα, IFNγ, IL-1β, IL-18, IL-6), 
chemokines (e.g. IL-8, MCP-1) and the up-regulation of cell surface molecules (TLRs and B7 
co-stimulatory molecules 12). The APCs internalise, process and present antigen to cells of 
the adaptive immune system to elicit a tailored, pathogen specific immune response. 
 
As well as APCs, oral epithelial cells play an active role in innate immunity. Epithelial cells 
had conventionally been thought of as immunologically inert, however, recent studies have 
shown that these cells can acquire immune cell characteristics by up-regulating the 
expression of pattern recognition receptors (PRRs)13 in response to signals from the 
basolateral surface. A number of oral epithelial cell lines and primary gingival epithelial cells 
are unresponsive to a selection of bacterial pathogen associated molecular patterns 
(PAMPs); LPS - a TLR4 ligand, peptidoglycan (PGN) and lipotechoic acid (LTA)  - TLR2 
ligands, and muramyl dipeptide (MDP) – a nucleotide-binding oligomerization domain 
containing 2 (NOD)2 ligand. Following pre-treatment with IFNγ, the cells become responsive 
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to PAMPs and up regulate interleukin (IL)-8 and granulocyte-macrophage-colony stimulating 
factor (GM-CSF) expression 14,15. This would suggest that epithelial cells are involved in the 
recruitment of neutrophils to the epithelial surface and differentiation of monocytes into pro-
inflammatory macrophages, respectively13. During inflammation, it is likely that there are high 
levels of IFNγ produced by T cells 16, rendering epithelial cells responsive to PAMPs. Thus, 
PAMPs provide the ‘danger’ signals needed to break tolerance and initiate an immune 
response, which oral epithelial cell immune responsiveness (activated by IFNγ) can 
perpetuate.  In contribution to their active role in mucosal immunity, oral epithelial cells 
express the bacterial LPS receptor, TLR4.  Although expression of its co-receptor, CD14, is 
low 17,18, oral epithelial cells can be rendered responsive to PAMPs via soluble, bio-active 
CD14 (sCD14) in the plasma and saliva13,19. sCD14 can form a complex with MD2, LBP, 
LPS and TLR4 11, rendering the CD14 negative cells responsive to LPS and inducing 
cytokine expression19. Interestingly, P. gingivalis has been shown to promote the shedding 
of membrane-bound CD14 from macrophages via the proteolytic enzymes, gingipains 20. 
This increase in soluble CD14 may render epithelial cells more responsive to microbiota that 
are normally tolerated by the mucosal immune system, but at the same time decrease 
macrophage intracellular signalling so that they cannot clear the P. gingivalis infection 
effectively, leading to epithelial damage but macrophage unresponsiveness.  
 
In addition to oral epithelial cells, gingival fibroblasts (GFBs) can mediate inflammatory 
responses to pathogens such as P. gingivalis. GFBs express TLRs 1,2,3,4,5,-6 and 9 21 and 
can produce inflammatory cytokines such as  IFNγ, IL-6, IL-1β, and IL-8, along with PGE2,  
ICAM-1 and HLA-DR 22–24. As such, GFBs may be involved in leukocyte recruitment, 
macrophage polarization, periodontal bone resorption, activation of epithelial cells, antigen 
presentation and induction of IL-2 production leading to T cell proliferation. Thus, GFBs and 
oral epithelial cells actively contribute to both innate and adaptive immune responses.  
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Communication between innate and adaptive immunity via antigen presentation is 
fundamental in the mucosal immune system. The oral cavity is sometimes considered 
simply an extension of the gastrointestinal tract, and whilst there are structural and 
functional similarities, the methods of antigen presentation differ in oral and gut mucosa. In 
the gut, mucosal microfold (M) cells internalise intra-lumenal antigens and present them to 
antigen presenting cells (dendritic cells (DCs) and macrophages (MФ)) in the lamina 
propria25. M cells are not present in the oral mucosa, thus intra-oral antigens are sampled by 
DCs extending spindly protrusions through the tight junctions of the epithelium. Rescigno et 
al.  (2001) demonstrated this mechanism with a model of the gut epithelium, using the gut 
epithelial cell line CaCO2  co-cultured in transwells with DCs on the basolateral side26. 
When non-invasive bacteria were added apically to the epithelial monolayer (not 
basolatterally), DCs upregulated the expression of tight junction proteins occludin and 
claudin1, and formed new, tight-junction-like structures with the epithelial cells. By utilising 
this pathway of transepithelial sampling, the integrity of the epithelial barrier remained 
intact26, whilst allowing the processing and presentation of antigen by DCs to induce an 
adaptive immune response. 
The adaptive immune response in the oral mucosa 
Following the initiation of an innate immune response, a pathogen-specific adaptive 
response is required to eliminate infection. Under physiological conditions, effector T helper 
(TH) cell subsets TH1, TH2, and the newly-described TH17 provide immune protection against 
a particular range of pathogens 27. TH1 cells defend the host against infection by intracellular 
bacteria and viruses (part of the cell-mediated immune response), and TH2 cells provide 
defence against extracellular bacteria and parasites (part of the humoral immune response) 
27. TH17 cells help eradicate fungi and both intra-and extra-cellular bacteria and have been 
implicated in mucosal immunity 28,29. Dysfunction of Th2 or TH1/ TH17 leads to the 
development of allergy and autoimmunity, respectively. Under physiological conditions, 
regulatory T cells (Tregs) express high levels of the anti-inflammatory cytokines IL-10 and 
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TGF-β in order to suppress effector T cell function when an immune response is not 
needed30.  
Differentiation of T helper cell subsets is dependent on the cytokines/cell-cell stimuli they 
encounter 27. TH1 are differentiated from naive precursors (dependant on the transcription 
factor T-bet) in the presence of IL-12 expressed by APCs 16. TH1 express IL-2 needed for 
their proliferation, and IFNγ 27 which activates pro-inflammatory macrophages31–33, initiating 
a cell mediated immune response. TH2 are differentiated (dependant on GATA-3 
34) in the 
presence of IL-4 expressed by APCs. They express high levels of IL-10, IL-4 and IL-13 16, 
which suppress the differentiation of TH1/ TH17, and promote a humoral immune response, 
and the differentiation of anti-inflammatory M2 macrophages31–33. 
 
Figure  1-1: Schematic representation of APC driven T helper cell differentiation 
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TH17 express high levels of IL-17, IL-21 and IL-22
35,36, which act on mucosal epithelial cells  
37 to produce inflammatory cytokines and chemokines (such as TNFα and IL-8 38) and 
antimicrobial peptides (such as β-defensin 2 35). IL-1β, IL-6, IL-21, IL-23, TNFα  and TGF-β 
(in a seemingly concentration-dependent manner) have all been implicated in TH17 
differentiation39, although the involvement of TGF-β has been hotly debated 40,41. Low-
concentrations of TGF-β in combination with pro-inflammatory cytokines such as IL-6 may 
lead to TH17 development, whereas high levels of TGF-β lead to Treg differentiation, which 
is amplified by the presence of retinoic acid 39,42. Nevertheless, TH17 differentiation is 
dependent on the transcription factors RORγt and RUNX1 43.  
In cells stimulated with TGF-β alone (Treg-priming conditions), RUNX1 binds to Foxp3 to 
promote IL-10 expression and suppresses RUNX1/RORγt binding, thus silencing IL-17 
expression 44. In cells stimulated with TGF-β + IL-6/IL-21 (TH17 conditions), RUNX1 binds to 
RORγt and suppresses RUNX1/Foxp3 binding, thus silencing IL-10 expression 44. Given the 
close, reciprocal regulation of anti-inflammatory Tregs and pro-inflammatory TH17 
differentiation, it is possible that a genetic polymorphism in RUNX1 leads to the loss of Treg 
suppressive activity and promotion of a destructive TH17 response in the oral mucosa. 
Indeed, such a polymorphism has been identified in other chronic, inflammatory diseases 
such as rheumatoid arthritis45, systemic lupus erythematosus 46  and psoriasis 47. 
Furthermore, IL-17 producing T cells have been associated with periodontal lesions 48,49 and 
even oral cancer 50.  
In oral cancer, invasion, migration and cervical metastasis of cancer cells is driven by MIP-
3a, a T cell chemokine 51. Lymphocytes isolated from oral tumour infiltrates produce  high 
levels of IL-1β , IL-6, TNFα and TGF-β compared with cells isolated from peripheral blood 52. 
CD4+CD25+ T cells isolated from peripheral blood mononuclear cells (PBMC) and tumour 
sites in oral cancer patients also express Treg markers, FoxP3, GITR, CD45RO, CD69, LAP, 
CTLA-4, CCR4, and IL-10. These cells exhibited a more suppressive effector function than 
the equivalent cells isolated from healthy patients. FoxP3 was also detected in T cells 
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isolated from peripheral blood, suggesting that oral tumours suppress anti-tumoural immune 
responses both locally and systemically 53. CD4+FoxP3+ IL-17-producing T cells also infiltrate 
the tumour microenvironment 50.  TH17 cells were found in patients with early stage cancer, 
but switch to a prevalence of Tregs a later stages in disease 52 
Anti-tumoural responses are hypothesised to be mediated by a phenomenon called cancer 
immunoediting.  54. Cancer immunoediting  has 3 stages: elimination, equilibrium and escape 
55. During the elimination phase, the immune system is alerted to malignant transformation 
via danger signals, and transformed cells are deleted. Tumour antigen presentation by APC 
to CD8+  cytotoxic T cells (Tc) is required for tumour rejection 5657 and IFNγ is indispensable 
in this tumour cell killing 55. In the equilibrium phase, the immune system exerts more 
selection pressure on the transformed cells, which in turn develop further mutations, 
resulting in a continuum of eradication and emergence of newly transformed cells. Escape 
from this stage may be promoted by the pro-tumoural actions of tumour associated immune 
cells, described later in this chapter.  
Oral Mucosal Tolerance 
The oral mucosa is a complex immune site that discriminately responds to pathogenic 
microorganisms and disregards commensals and dietary antigens. This mechanism of 
discretionary non-responsiveness is described as ‘oral mucosal tolerance’. It is due to this 
immunological phenomenon that we do not elicit an immune response to food antigens or 
commensal microorganisms, but retain the capacity to orchestrate a deadly assault on 
pathogens when required. This is the fundamental role of the oral mucosal immune system. 
To prevent constant (and inappropriate) immune activation, the oral mucosal immune 
system has in place a variety of mechanisms to suppress activation and induce a state of 
immune ‘tolerance’ to antigenic stimuli.  
Dendritic cells in peripheral tissues, such as dermal Langerhans cells (LC), are found in an 
immature state and constitutively endocytose antigens of microbial or self-origin58. This is a 
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key factor in mucosal tolerance: endocytosis alone does not lead to DC activation. This 
mechanism of internalisation without activation leads to the presentation of antigen and 
apoptotic material to T cells without co-stimulation, thus inducing T cell non-responsiveness 
(anergy) 58. If these DCs remain un-stimulated, they do not up-regulate their expression of 
co-stimulatory molecules and become tissue resident LCs58. However, it has been reported 
that LCs of the oral mucosa express high levels of Fc receptors (FcRs), co-stimulatory 
molecules and MHC I and II 59. The lack of CD83, a marker of mature DCs in oral LCs 
suggests that they are in an immature state 59, and these immature DCs would not be 
expected to express co-stimulatory molecules58. Thus, LCs of the oral mucosa have the 
potential to be highly immunogenic, yet under physiological conditions, the oral mucosal 
immune system maintains a state of tolerance. It is likely then that oral LCs maintain 
tolerance via different mechanisms. For instance, ligation of FcεR1 by IgE on monocytes 
leads to the expression of IL-10, and up-regulates Indoleamine 2, 3-Dioxygenase (IDO) 
activity 60,61, leading to suppression of effector T cell activity. Is it possible that a similar 
mechanism is utilized in the oral LCs; in fact, isolated oral LCs have been shown to produce 
IL-10 in response to stimulation via TLR4, and induce tolerogenic Foxp3+IL-10+ and TGF-β+ 
Tregs 25,60 suggesting that they actively contribute to maintaining oral mucosal tolerance. 
 
The presence of oral microbiota is also likely to play a role in mucosal immune homeostasis. 
Commensal microflora have been shown to maintain a constant presence of APCs at the 
epithelial surface 14. Repeated stimulation of APCs by bacterial PAMPs can also have a 
tolerising effect, for example, LPS from P. gingivalis has been shown to down regulate the 
expression of TLRs 2 and 4 on macrophages in response to repeated stimulation, and the 
expression of pro-inflammatory cytokines is decreased in accordance62. In addition, 
circulating, naturally occurring Tregs (nTregs) patrolling the tissues release anti-inflammatory 
cytokines to suppress unnecessary effector T cell activity63. They express IL-10, which 
blocks TH1 and TH17 differentiation, and TGF-β, which induces the release of more IL-10 
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(which can also promote a TH2 immune response), generating an anti-inflammatory 
environment and suppression of inappropriate pro-inflammatory effector responses; i.e. 
tolerance 63. This level of tolerance is maintained by a low dose of antigen, and small 
amounts of IL-2. High levels of pro-inflammatory cytokines expressed by DCs and 
macrophages, such as IL-6, can ‘switch off’ Tregs by blocking their activation64, leading to an 
effector T cell response. Given that oral mucosal tolerance is maintained by a concurrent 
array of complex mechanisms, dysregulation in any one part may lead to a breakdown in 
tolerance and uncontrolled immune activation in response to oral microbiota.  
 
Aberrant innate cell function leads to pathology in the oral mucosa – key role of 
macrophages 
 
Macrophages prime the adaptive immune response according to the differentiation and/or 
activation signals they encounter 31–33 . They have been shown to play a vital role in driving 
chronic inflammatory conditions such as rheumatoid arthritis (RA) 65 and Crohn’s disease 
66,67.  They can be divided into distinct subsets according to their cytokine profile and 
phenotypic traits. Classical, pro-inflammatory macrophages (M1) are polarized by 
granulocyte macrophage-colony stimulating factor (GM-CSF) and activated by IFNγ 
produced by TH1
31–33. Alternative, anti-inflammatory macrophages (M2), lead to the 
generation of a TH2 response and are polarized by M-CSF 
31–33. They can be further divided 
into subsets; M2a – activated by IL-4 and IL-13, M2b – activated by immune complexes + 
LPS and TLR ligation, and M2c - activated by IL-10 32,68.  M2 type macrophages exhibit anti-
inflammatory properties and express the regulatory cytokines, IL-10 and TGF-β which 
negatively regulate M1. M1 type macrophages express high levels of pro-inflammatory 
cytokines, TNFα, IL-1β, IL-18, IL-6, IL-12 and IL-23 32. Thus, polarisation of macrophages to 
an M1 phenotype favours a pro-inflammatory response and M2 differentiation favours an 
anti-inflammatory / regulatory response. Aberrant activation of M1 and M2 leads to 
development of inflammatory conditions (such as periodontitis) and immunosuppressive 
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conditions, such as oral cancer, respectively.  Periodontitis is a chronic inflammatory disease 
affecting the supporting structures of the teeth (periodontium). Previous studies have shown 
that the oral pathogen Porphyromonas gingivalis plays a significant role in the development 
of periodontitis 69. 
 
Immune function in periodontitis 
 
P. gingivalis and oral epithelial cell interactions 
 
Porphyromonas gingivalis is a gram-negative, anaerobic, rod-shaped and black pigmented 
bacterium70. The vast array of potential virulence factors produced by the bacterium can 
initiate destruction of periodontal tissue71. In the gingival sulcus, neutrophils form a barrier 
between the epithelium and the plaque biofilm 72 which serves to protect the epithelium from 
invasion73. However, P. gingivalis can circumvent killing by neutrophils and adhere to 
epithelial cells. Upon adherence, P. gingivalis can rapidly invade the epithelial cells by 
binding of its major fimbriae to β1 integrin receptors74 and remodelling the actin cytoskeleton 
via phosphorylation and activation of FAK (focal adhesion kinase) and paxillin 74. Invasion of 
epithelial cells allows P. gingivalis to evade recognition by the host immune system. Once 
inside the cells, P. gingivalis resides in the cytoplasm and accumulates around the nucleus 
75. There, P. gingivalis can hijack host cytoskeletal machinery to facilitate the formation of 
intercellular tubules, allowing for safe passage to the neighbouring cells 74. Thus, epithelial 
cells are chronically exposed to P. gingivalis. Furthermore, P. gingivalis  has been detected  
within epithelial cells at sites remote from its usual, sub-gingival habitat, such as the buccal 
epithelium76. 
Oral epithelial cells and P. gingivalis exhibit a dynamic relationship; upon invasion of 
epithelial cells, P. gingivalis induces major changes in its gene transcription and protein 
expression profiles 77,78, which in turn modulates transcriptional response of the epithelial 
cells 79. Thus, P. gingivalis and GEC adapt to facilitate long-term cohabitation. Epithelial cells 
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survive for up to 8 days after infection 80, allowing intracellular P. gingivalis to remain viable 
and spread between host cells 81, and evading recognition by immune cells.  
P. gingivalis employs several mechanisms to avoid eradication by the immune system. It can 
inhibit chemically induced apoptosis in GECs by blocking activation of the effector caspase-3. 
The anti-apoptotic phenotype of P. gingivalis is conserved across strains and does not 
depend on the presence of fimbriae, as fimbriae-deficient strains were able to impede 
apoptosis. P. gingivalis infection promotes a survival of epithelial cells by inhibition of 
mitochondrial cell death pathways via phosphorylation of JAK1 and Stat3, and increased 
expression of Survivin and Stat3 82. However, in gingival fibroblasts, pro-apoptoic pathways 
are up-regulated by prompting translocation of apoptosis inducing factor to the nucleus 
indicating that P. gingivalis causes fibroblast apoptosis through a pathway independent of 
proteolytic activity and the classical apoptotic pathways involving caspase-3 83. P. gingivalis 
also suppresses the adaptive, anti-microbial T-cell responses by up-regulating IL-10 and PD-
1, which in turn inhibits IFNγ production 84, and up-regulates the expression of the tolerance-
inducing molecules B7-H1 and B7-DC receptors in gingival keratinocytes. 85 
 
Porphyromonas Gingivalis  LPS and Toll like receptor interactions 
 
 
LPS is a virulent molecule located in the outer membrane of gram negative bacteria. 
Traditionally, LPS consists of inner and outer core regions, an external O-antigen 
(recognised by antibodies), and is anchored to the bacterial membrane by lipid A86. The lipid 
A portion of LPS consists of a glucosamine disaccharide backbone with fatty acid residues 
attached. Lipid A is the bioactive component of LPS and confers its biological activity by 
binding TLR4 and myeloid differentiation factor 2 (MD-2) on host cells87. The fatty acids, of 
which there are traditionally 6 (hexa-acytlated), such as in the archetypal enterobacteria E. 
28 
 
coli LPS, fit precisely into the binding pocket of MD-2 88. This initiates dimerization of the 
TLR4/MD-2 complex and an intracellular signalling cascade, leading to activation of 
transcription factors and production of inflammatory cytokines87. Lipid A is a structurally 
conserved pathogen associated molecular pattern (PAMP), but its conformation can vary by 
the number of fatty acids, where the fatty acids are linked to the glucosamine backbone, and 
the number of phosphate groups89,90. P. gingivalis lipid A has several unusual properties that 
distinguish it from E. coli Lipid A. First determined in 1993 by Ogawa et al89, P. gingivalis 
lipid A has a tri-acylated, mono-phosphorylated chemical structure, that is, it consists of 2 
glucosamine molecules (β-(1–6) linked) making up the disaccharide backbone, with 3 fatty 
acids (2 molecules of 3-hydroxy-15-methylhexadecanoic acid and 1 molecule of 3-
hexadecanoyloxy-15-methylhexadecanoic acid) at the 2- and 2'-positions of the disaccharide 
backbone, respectively 89. Later, it was discovered that P. gingivalis also produces lipid A 
species of the tetra- and penta- acylated forms, with the extra fatty acids linked to the 3 and 
3′ positions91. Furthermore, P. gingivalis lipid A is distinct from E. coli lipid A in that it has 
no phosphate at the 4'-position (E. coli  lipid A is phosphorylated at the 1 and 4' positions), 
and it has fatty acids that possess more carbon atoms (16–17 atoms)89. 
It is thought that these differences in lipid A conformation in P. gingivalis are responsible for 
its unusual biological activity. P. gingivalis LPS contains a heterogenous compilation of lipid 
A species, which are mostly tri- and tetra-acylated lipid A92. This results in a less precise 
binding of the fatty acids to the binding pocket in MD-2, and a consequent lower level of 
bioactivity. As well as the number of fatty acid residues, the number of phosphate groups of 
lipid A can also affect biological activity. Curtis et al (2011) have shown that P. gingivalis 
grown under stress conditions (elevated temperature simulating oral inflammation) will 
change its lipid A conformation: P. gingivalis grown at 41º C produces mostly mono-
phosphorylated, penta-acylated lipid A, whereas P. gingivalis grown at 37ºC produced 
mostly non- and mono- phosphorylated, tetra-acylated lipid A. As the lipid A conformation 
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changed with temperature increase, the virulence of the lipid A increased, leading to more 
potent activation of TLR4 (measured by NFκB activation)92. 
In addition to biological activity being affected by the number of fatty acid residues and 
phosphate groups in lipid A, it is also affected by the position of the phosphates. Like P. 
gingivalis, several bacterial species produce a lipid A that is penta-acyltated and non-
phosphorylated, which does not activate TLR4 93. However, P. gingivalis also produces a 
mono-phosphorylated, penta-acylated form, and it is the unusual position of the phosphate 
(at the 4′ position) that confers its lower immunogenicity93 (Coats, 2011).This is exemplified 
by the fact that P. gingivalis LPS has consistently been demonstrated to exert lower 
endotoxin activity (lower cytokine production) in many studies, including this one. 
The TLR signalling pathways utilised by P. gingivalis have been contested for a number of 
years. In a recent review, Kirkwood et al. suggest that P. gingivalis LPS preferentially utilizes 
toll-like receptor-2 and not toll-like receptor-4 94–96 as previously thought. However, other 
studies report that it is down to contaminants (namely lipoprotein) during the purification 
process which lead to the activation of TLR291. It is important to determine the utilisation of 
either TLR2 or TLR4 by P. gingivalis, as activation of either pathway may result in differential 
activation of the adaptive immune response in periodontal lesions. Studies have reported 
that P. gingivalis LPS binds TLR4 in gingival fibroblasts 97, and promotes IL-12p70, IFNγ, 
and production of other Th1-associated cytokines 98. In contrast, other studies indicated that 
in response to TLR2 activation these cytokines were produced in much smaller amounts, or 
not at all, 96,99,100 suggesting that TLR2 stimulation, in the absence of simultaneous TLR4 
stimulation, favours the development of a Th2-like immune response. It has now been 
generally accepted that Th1 cells are associated with (early) stable periodontal lesions, while 
Th2 cells are associated with progressive lesions 101,102, however, evidence is gathering for 
the involvement of Th17 cells in periodontitis. Indeed, P. gingivalis induces Th17 associated 
cytokines IL-1β, IL-6 and IL-23, but not Th1 related IL-12 from APCs in periodontitis. 
Furthermore, P. gingivalis gingipains preferentially degraded Th1 associated cytokines, 
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skewing the inflammatory microenvironment towards a Th17/tissue destructive type, 
associated with autoimmunity103. 
A further mechanism possessed byP. gingivalis to induce autoimmunity is via the molecular 
chaperone GroEL. GroEL and human heat shock protein HSP 60 show marked structural 
similarity, and both are expressed in higher levels in periodontitis tissues than control tissue 
104. P. gingivalis GroEL binds to both TLR2 and TLR4 to induce NF-κB activity in monocytes 
105, ,however, in a separate study it was reported that it was human HSP 60not P. gingivalis 
GroEL that activated monocytes up-regulated TNFα production to similar levels induced by 
P. gingivalis  LPS 106. Nevertheless, human HSP 60 is recognised by antibodies raised to P. 
gingivalis  GroEL 106,107, thus providing a potential mechanism of autoimmune tissue 
destruction induced by P. gingivalis  infection seen in periodontitis. Heat shock protein 
families and P. gingivalis infection are implicated in other chronic inflammatory conditions, 
such as rheumatoid arthritis 108 and atherosclerosis 109,110.  
Periodontal disease and its systemic implications 
 
There have been many studies into links with systemic inflammatory diseases and 
periodontitis. There is evidence to support the relationship between human periodontal 
disease and an increased risk for acute myocardial infarction111–113. Furthermore, several 
bacteria associated with periodontal disease, including P. gingivalis, have been detected in 
atherosclerotic plaque 111,114,115. Serum antibodies to P. gingivalis have also been associated 
with coronary heart disease 112. It has been suggested that periodontal disease can lead to 
low-level bacteremia, an elevated leukocyte count, and systemic endotoxemias, which could 
affect endothelial integrity, metabolism of plasma lipoproteins, blood coagulation, and 
platelet function. Furthermore, it is well established that infection with P. gingivalis induces 
local inflammation, which can lead to gingival ulceration and local vascular changes, which 
have the potential to increase the incidence and severity of transient bacteremias. Several 
studies have also demonstrated that patients with periodontal disease have elevated levels 
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of systemic inflammatory mediators. Extensive periodontal disease has been associated with 
increased levels of C-reactive protein (CRP)116; moderately elevated CRP is a systemic 
marker of inflammation and a documented risk factor for cardiovascular disease117. 
It has long been established that infection with particular bacteria or viruses can lead to the 
malignant transformation of epithelial cells; the enterobacterium Helicobacter pylori, for 
example,  is a recognised gastric carcinogen118. Evidence is accumulating that the 
periodontal pathogen has a role in the development of oral cancer 119–121 
Immune function in oral cancer 
 
More than 90% of malignancies of the oral cavity are squamous cell carcinomas (OSCC), 
and as of 2010, holds sixth position in the ranking of cancer incidence worldwide 122,123 Most 
prevalent in males 124, OSCC is a multifactorial disease and its initiation  has been linked to 
oral leukoplakia 125, HPV infection 126, periodontal disease 127, oral bacterial species 128, 
alcohol and tobacco use 129,130. In the Western nations, the increase in incidence of OSCC 
among younger cohorts may be related to HPV transmission 126.   
 A key feature of OSCC is the infiltration of immune cells, including lymphocytes, neutrophils, 
eoisinophils and monocytes 131. Once recruited to the tumour site by chemotactic factors 
such as MCP-1, expressed more highly in OSCC tissue than normal mucosa  132, monocytes 
differentiate into macrophages and can polarise into M1 or M2 -like subsets with pro- and 
anti-tumoural properties. These tumour-associated macrophages (TAM) have been subject 
to intense investigation. 
Macrophages in oral cancer 
Characteristically, M1 macrophages amplify TH1 responses, providing a positive feedback 
loop in the anti-tumour response 133 However, in the tumour microenvironment, these 
responses can be overridden and macrophages then facilitate tumour progression 134 . 
Compared with macrophages within the surrounding tumour stroma, macrophages in direct 
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contact with cancer cells display impaired tumour antigen presentation due to low lysosome 
expression and defective phagosome-lysosomal apparatus. Highlighting the influential role 
of tumour cells over macrophage function 73. TAMs can be modulated by tumour cells to 
facilitate tumour growth and survival. They can induce immune suppression via production of 
anti-inflammatory cytokines such as IL-10 and TGF-β, production of angiogenic factors 
(VEGF) (reviewed in135), and inhibition of tumour antigen presentation by down-regulating 
MHC molecules and up-regulating inhibitory co-stimulatory B7 molecules 136. IL-10 and TGF-
β can further inhibit the anti-tumoural response by inducing Treg differentiation 137. Recently, 
pro-inflammatory cytokines (presumed to be anti-tumoural), have been shown to play a 
detrimental role in cancer. In response to pathogenic stimuli, macrophages produce 
inflammatory mediators such as reactive oxygen and nitrogen species, and cytokines (such 
as TNFα, IL-1β, IL-6 and IL-8), leading to oxidative and nitrative DNA damage 138, enhanced 
cell growth and proliferation, inhibition of apoptosis and production of angiogenic factors 
(reviewed in 135). TNFα and IL-6 are associated with poor prognosis in several carcinomas 
139–141, and inhibitors of both are in clinical trials for the treatment of cancer 142,143. 
 
TAMs display broad heterogeneity, differing both across and within disease sites. Monocytes 
stimulated with breast cancer supernatants increase expression of IL-10, IL-8, and the M2-
associated chemokines CCL17 and CCL22 (T cell chemoattractants binding CCR4). 
However, upon culture with colon cancer cell supernatants, monocytes produced more of the 
M1-assocaited factors IL-12, TNFα, and ROS 144. In breast cancer tumours, at least two 
distinct TAM populations have been identified. These TAMs differentially express CD206 
and MHC II, and display distant behavioural profiles; sessile, M2 -like macrophages found in 
hypoxic regions and at the tumour borders, and migratory macrophages (less resembling the 
M2 phenotype) which are found perivascularly 145. Therefore, there is a very complex 
relationship between tumours and their associated macrophages, and TAM behaviour 
should be studied in a disease specific context, rather than inferred from other cancers. 
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In OSCC, macrophages expressing CD163 (an M2 marker) were found in elevated numbers, 
particularly in advanced lesions, and this significantly correlated with a poor outcome in 
patients with OSCC 146. Macrophages expressing high levels of M2-associated cytokines IL-
10 and TGF-β have also been found in elevated numbers in OSCC microenvironments, and 
higher numbers of macrophages were present in metastatic versus non-metastatic OSCC. 
This led to a shorter survival time in patients with a higher percentage of TAMs, than patients 
with low TAM infiltration 147.    
 
In general, tumour-associated macrophages (TAMs) acquire an M2-like phenotype 148, but in 
colorectal cancer and non-small cell lung carcinoma, the infiltrating macrophages display a 
more pro-inflammatory, M1-like phenotype 149,150, and some even develop into a mixed 
M1/M2 phenotype 151. However, in the tumour environment, macrophages exhibit 
extraordinary plasticity, adapting their phenotype and effector functions in response to local 
stimuli 148. It has been demonstrated both in vivo and in vitro that macrophage polarisation 
can be reversed by exposure to opposing polarising factors 152,153. This plasticity can be 
exploited to develop anti-cancer therapies 152. For example, the M1-polarising cytokine IFNγ 
reverses the anti-inflammatory/suppressive properties of TAMs 154. TAMs can also be 
switched to an anti-tumour phenotype by blocking NFκB signalling 49.  Thus, localised IFNγ 
treatment or inhibition of NFκB signalling (specifically via activation of IKKβ) make suitable 
candidates for therapeutic development. A further mechanism proposed to modulate TAMs 
toward a more pro-inflammatory, anti-tumoural activation state, is bacterial LPS. LPS or 
analogues thereof have been used in human clinical trials as an anti-cancer therapy 155–158. 
The effects of LPS on OSCC cells has yet to be described. 
Given the fundamental role macrophages play in driving both inflammatory (periodontitis) 
and immunosuppressive (cancer) conditions, investigating how their functions are affected 
by these disease states will provide insight into their pathogenic mechanisms. What is more, 
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these interactions have been implicated in diseases at sites distant from the oral mucosa, 
and so may have wider reaching implications in macrophage driven pathology in general.  
Thus, the main objectives of the present study are as follows:  
• To establish a robust, reproducible model of M1 and M2 macrophage polarisation 
using the THP-1 cell line, so that their interactions with pathogenic oral bacteria can 
be investigated.   
• To determine what effect the presence of P. gingivalis LPS during the macrophage 
polarisation process has on cytokine expression in response to subsequent LPS 
stimulation 
• To determine the cytokine response of the OSCC cell line H357 to P. gingivalis LPS. 
• To determine the effect of OSCC produced soluble factors on macrophage 
polarisation and subsequent responses to P. gingivalis LPS. 
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Chapter 2  – Materials and methods 
Materials and reagents 
The materials and reagents used in the study are listed in Table 2-1. 
Table  2-1: List of reagents used in the study 
Product Product code Supplier 
Accutase cell detachment solution 00-4555 eBioscience, UK 
Anti-Human CD282 (TLR2) PE 12-9922-41 eBioscience, UK 
Anti-Human CD282 (TLR4) PE 12-9917-41 eBioscience, UK 
BSA A7906-100G Laboratory Analysis Ltd 
DMEM BE12 – 614F Lonza, UK 
DNAse kit AMPD1-1KT  Sigma, UK 
DPBS Ca2+ and Mg2+ free BE17-512F Lonza, UK 
Escherichia coli K12 LPS tlrl-peklps  Invivogen, UK 
Foetal bovine serum S07313S1810/500 LabTech, UK 
H357 cells        - University of Sheffield, UK 
Ham’s F12  BE12-615F Lonza, UK 
Heat-killed Porphyromonas gingivalis Tlrl-hkpg Invivogen, UK 
IL-10 capture 554705 R&D systems 
IL-10 standard 93/722 NIBSC 
IL-10 detect 554499 R&D systems 
IL-12p70 capture 555065 R&D systems 
IL-12p70 detect 554660 R&D systems 
IL-12p70 standard 95/544 NIBSC 
IL-15 capture 554712 R&D systems 
IL-15 detect 554713 R&D systems 
IL-15 standard 95/554 NIBSC 
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IL-1ra capture MAB280 R&D systems 
IL-1ra detect BAF280 R&D systems 
IL-1ra standard 92/644 NIBSC 
IL-1β capture antibody  MAB601  R&D Systems, UK 
IL-1β detection antibody  BAF201 R&D Systems, UK 
IL-6 capture antibody 554543 R&D Systems, UK 
IL-6 detection antibody 554546 R&D Systems, UK 
L-Glutamine 200nM BE17-605E Lonza, UK 
Mouse IgG1 isotype control-PE IC002P R&D Systems, UK 
Mouse IgG2 K isotype control PE 12-4724-41 eBioscience, UK 
Mouse monoclonal anti- human TLR2 
neutralising antibody 
ab45054 AbCam, UK 
Mouse monoclonal anti- human TLR4 
neutralising antibody 
ab30667 AbCam, UK 
PAM3CSK4 tlrl-pms Invivogen, UK 
Phosphate buffered saline tablets P4417-100TAB Sigma Aldrich, UK 
Porphyromonas gingivalis 2561 33277 ATCC 
Recombinant human IFNγ 285-IF-100 R&D Systems, UK 
Recombinant human IL-1β 86/680 NIBSC 
Recombinant human IL-4 204-IL-010 R&D Systems, UK 
Recombinant human TNFα  210-TA-010 R&D Systems, UK 
RMPI 1640 BE12-167F/12 Lonza, UK 
Streptavidin HRP  DY998 R&D systems 
TGF-B1 capture 555052 R&D systems 
TGF-B1 detect 555053 R&D systems 
TGF-B1 standard 89/514 NIBSC 
THP-1 cells TIB-202 ATCC 
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TMB microwell peroxidase 50-76-00 Insight Biotechnologies UK 
Tween 20 P1379 Laboratory analysis, UK 
Ultrapure Porphyromonas gingivalis LPS Trlr-pglps Invivogen, UK 
(LAL) assay (KQCL kit)  
 
 
 
50-650U Lonza Ltd, UK 
 
Table  2-2: List of primer sequences and suppliers 
Target gene Sequence Supplier 
Human IL-10 Forward CAA AAC CAA ACC ACA AGA 
CAG ACT 
Eurofins MWG Operon, 
UK 
Human IL-10 Reverse CAG GAG GAC CAG GCA ACA 
GA 
Eurofins MWG Operon, 
UK 
Human TGF-β1 Forward AGT TCA AGC AGA GTA CAC 
ACA GCA T 
Eurofins MWG Operon, 
UK 
Human TGF-β1 Reverse AGA GCA ACA CGG GTT CAG 
GTA 
Eurofins MWG Operon, 
UK 
Human β actin Forward ATT GCC GAC AGG ATG CAG 
AA 
Eurofins MWG Operon, 
UK 
Human β actin Reverse GCT GAT CCA CAT CTG CTG 
GAA 
Eurofins MWG Operon, 
UK 
Primers were either selected from published literature or designed using Applied Biosystems 
software.  
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General cell culture: Cell lines and growth conditions 
THP-1 
THP-1 (ATCC, TIB-202) are a monocytic cell line derived from a one-year old male with 
acute myeloid leukaemia. Cells were ressuraected from liquid nitrogen at passage 9 and 
cultured in RPMI 1640 (Lonza, UK) supplemented with 10% foetal calf serum (LabTech, UK) 
and 1% L-glutamine (Lonza, UK) in a humidified incubator at 37oC with 5% CO2. Cells were 
initially seeded at 4 x 105 cells/ml and routinely sub-cultured using 1:4 split ratios and 
maintained for no more than 10 passages THP-1 cell culture media is referred to as R10 
throughout this thesis. 
H357 
H357 cells were a kind gift from Professor Stephen Prime/Dr Simon Whawell, University of 
Sheffield. Cells were seeded in tissue culture treated flasks at 5 x 103 cells/ml in 1:1 DMEM 
and Ham’s F12 (Lonza, UK), supplemented with 10% foetal calf serum and 1% L-glutamine. 
Cells were grown to 70-80% confluence then sub-cultured using AccutaseTM cell detachment 
solution (eBioscience). H357 culture media is referred to as HM throughout this thesis. H357 
were cultured in serum because it has been previously reported that serum must be present 
for epithelial cells to respond to LPS 159 
Primary tissue collection and culture 
 
All samples of primary tissue were collected from Derriford Hospital (Plymouth, UK) and the 
Royal Devon and Exeter hospital (Exeter, UK) with full patient consent. The study was 
approved by the NRES Committee South West - Cornwall & Plymouth in September 2009, 
study number: 09/H0203/78.  
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Collection of control (non-tumour) mucosa: 
 
Following routine wisdom tooth extraction, 0.5cm of the least inflamed mucosa from the 
distal incision was collected prior to placement of sutures. The excised tissue was placed in 
7ml bijou tube containing culture medium, which was then tightly sealed with parafilm and 
kept on ice until processed.  
Collection of oral squamous cell carcinoma tissue: 
 
Following excision of tumour for biopsy, a section of the tumour was removed (see 
Figure  2-1) and placed in 7ml bijou tube containing culture medium, which was then tightly 
sealed with parafilm and kept on ice until processed.  
 
 
 
 
 
 
 
 
Generation of M1- and M2- like THP-1 macrophages 
Method adapted from Tjiu et al 160. 5 x 105 THP-1 cells were seeded in tissue culture plates 
and incubated with 5 ng/ml PMA for 6 hours. Next, all the culture media was removed, 
including any non-adhered cells and was replaced with fresh media containing either (a) 5 
ng/ml PMA, (b) 20 ng/ml IFNγ + 5 ng/ml PMA (c) 20 ng/ml IL-4 + 5 ng/ml PMA or (d) 20 
ng/ml IL-10 + 5 ng/ml PMA for a further 18 hours to generate PMA controls (MΦPMA), M1-like 
macrophages (MΦIFNγ) and  M2-like macrophages (MΦIL-4,), respectively . 
Figure  2-1: Diagram of tumour tissue samples used in the study 
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Figure  2-2: Schematic representation of macrophage polarisation protocol 
Generation of H357 conditioned media 
To assess the effects of soluble factors produced by H357 on M1/M2 THP-1 polarisation, the 
usual polarisation protocol was followed (see Figure  2-2 ), but the cytokines (IFNγ/ IL-4/ 
PMA) were added to H357 -conditioned media instead of R10. Conditioned media was 
generated by growing H357 to confluence in 75cm2 tissue culture flasks for 6 days. Culture 
media was removed and replaced with fresh media. After 24 hours incubation, the fresh 
media was collected and centrifuged (IEC Centra CL3R, International Equipment Company, 
UK) at 230 G for 5 minutes to remove any cells that had become loose in the medium. 
Conditioned media was transferred to a sterile 25ml universal tube and stored at -20ºC until 
used in experiments.  
LPS biological activity assay: Limulus Amebocyte Assay (LAL)  
 
The presence of LPS in conditioned medium used to stimulate the cells was assayed by a 
kinetic Limulus Amebocyte Lysate (LAL) assay (KQCL kit, Lonza Ltd, UK) according to the 
5 ng/ml PMA 
+ 20 ng/ml IL-4 
THP-1 
cell 
MΦIL-4 
5 ng/ml PMA 
THP-1 
cell 
MΦPMA 
5 ng/ml PMA 
+ 20 ng/ml 
IFNγ  
THP-1 
cell 
MΦIFNγ 
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manufacturer’s instruction. Briefly, a stock endotoxin standard (50 endotoxin units (EU)/ml) 
was prepared and vortex-mixed for 15 minutes. A 4 point standard dilution of 0.005, 0.05, 
0.5 and 5 EU/ml was then prepared in pyrogen free glass tubes. The conditioned medium 
was diluted 1:10 and 1:20 and was heated at 75oC for 10 minutes. The assay was then set 
up by adding 50µl of each standard dilution and the test dilutions from the conditioned 
medium in duplicate wells on LAL reagent grade 96 wells plate (Lonza Ltd, UK). The plate 
was incubated for 10 minutes at 37oC inside the ELX808 Absorbance plate reader (Lonza 
Ltd, UK). In the meantime, the LAL reagent was reconstituted by adding 2.6mL of pyrogen 
free water and swirled gently to mix. The re-constituted LAL reagent (50µL) was then added 
to each well and the absorbance was read for 100 minutes and the level of the endotoxin in 
the condition medium was determined using WinKQCLTM 3.1.1 Endotoxin Detection and 
Analysis software (Lonza Ltd, UK).  
 
H357 and THP-1 co-culture experiments 
The experiments to measure the effects of H357 -conditioned media on THP-1 polarisation 
raised the following questions: 
1) Does the effect of conditioned media on macrophage polarisation change if there is 
cross-talk between the macrophages and epithelial cells?  
2) Does co-culture with macrophages affect the H357 response to P. gingivalis LPS?  
To test if cross-talk between the H357 and THP-1 affected macrophage polarisation, a series 
of co-culture experiments were set up to measure trans-well cross talk between THP-1 and 
H357 Figure  2-3 a: co-culture. b: no co-culture control ).  H357s were harvested from culture 
flasks at approximately 70% confluence (or 6 days post subculture) and seeded into BD 
Falcon tissue culture inserts (VWR, UK) at 5 x 104 cells/cm2 and grown to a confluent 
monolayer. THP-1 were seeded into BD Falcon companion plates and polarised in the usual 
manor, with (a) or without (b) (Figure  2-3) H357s in a tissue culture insert suspended above 
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the well. After the usual polarisation process, the H357s in tissue culture inserts were 
removed and transferred to a fresh companion plate containing 2ml HM. H357s were then 
stimulated with 1µg/ml P. gingivalis  LPS or with media alone as a control. From the 
macrophages, the culture media was removed and replaced with fresh R10, with or without 
P. gingivalis LPS. Both cell lines were incubated with or without P. gingivalis LPS for 24 
hours and the cell free supernatants were harvested and stored at -20ºC until assay for 
cytokines by ELISA. 
 
Figure  2-3: Schematic representation of H357/THP-1 transwell co-culture system.  
BD Falcon tissue culture inserts containing 4.5 x 103 H357 cells (upper well). The larger 
wells of the companion plate (lower well) contain 1x106 THP-1 cells.  
 
Cell viability - Trypan blue exclusion test 
 
Viable cells with their membrane intact will not take up Trypan blue. To test for cell viability, a 
sample of cells (8µl) was mixed 1:1 with 0.4% Trypan blue (8µl) and transferred to a 
haemocytomer. All viable cells (refractive and pale) and all dead (un-refractive and blue) 
cells in 4, 16x16 squares were counted and percentage viability was calculated. Unless 
otherwise stated, all experiments were set up with >98% viability.  
THP-1 responses to P. gingivalis LPS 
To measure cytokine responses of polarised THP-1 cells to stimulation with various PAMPs 
(P. gingivalis LPS, E.coli LPS, heat-killed P. gingivalis, Pam3csk4) cells were polarised 
according to the afore mentioned protocol and stimulated with varying concentrations of 
PAMPs for 24 hours, unless otherwise stated within each chapter. Upon completion of the 
THP-1 
H357 
HM 
R10 
a 
THP-1 
R10 
b 
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incubation period, cell free supernatants were harvested and stored at -20°C until assay for 
cytokines by ELISA. Cells incubated in media alone served as negative controls. 
H357 responses to P. gingivalis LPS 
To assess the effects of P. gingivalis  LPS stimulation on cytokines production in H357s, 
cells were cultured in the usual way and seeded at a density of 5 x103 cells/cm2 in 96 well 
tissue culture microplates (IWAKI). Dose-response curves were generated by incubating 
H357s with P. gingivalis LPS at 1000, 100 or 10 ng/ml. H357 with culture medium alone 
served as negative controls. After 24 hours, the supernatants were collected and stored at -
20ºC until assay for cytokines by ELISA. 
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Enzyme Linked Immunosorbent Assay (ELISA) 
Concentrations of paired antibodies were optimised using the chequerboard technique (see 
appendix 1). Optimal concentrations were picked by ascertaining the lowest signal –to –
noise ratio.  
ELISA reagents: 
ELISA wash buffer:  500ml Distilled water  
   2.5 Phosphate buffered saline tablets (Sigma, UK) 
250µl Tween 20 
Blocking solution: 2% BSA in PBS 
Stop solution:   1M sulfuric acid (H2SO4) 
Antibodies: 
Human TNFα ELISA 
BD Pharmingen paired antibodies 
Capture antibody: Murine anti-TNFα Mab1 IgG1 
Detection antibody: Biotinylated murine anti-human TNFα Mab1  
TNFα standard (NIBSC, UK) 5 ng = 25µl 
Human IL-6 ELISA 
BD Pharmingen paired antibodies 
Capture antibody: Murine anti-IL-6 Mab1 IgG1 
Detection antibody: Biotinylated murine anti-human IL-6 Mab1  
IL-6 standard (NIBSC, UK) 5 ng = 25µl 
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Human IL-1β  ELISA 
BD Pharmingen paired antibodies 
Capture antibody: Murine anti IL-1β  Mab1 IgG1 
Detection antibody: Biotinylated murine anti-human IL-1β Mab1  
IL-1β standard (NIBSC, UK) 5 ng = 25µl 
 
Table  2-3 Concentrations of antibodies used in ELISA 
Cytokine Capture antibody (µg/ml) Detection antibody 
(µg/ml) 
TNFα 4 0.5 
IL-1β 1 0.5 
IL-6 4 0.5 
 
General ELISA protocol 
50µl/well capture antibody in phosphate buffered saline (PBS) was added to a 96 well 
microtiter plate. Following overnight incubation at 4oC, unbound antibody was washed x3 in 
ELISA wash buffer and non-specific binding was blocked by incubation with 150µl/well 
BSA/PBS (2%) at room temperature for 4 hours. A standard curve for each cytokine from 
5000-7pg/ml was prepared in R10 and used at 1 in 3 serial dilutions. Standards and test 
samples were added at 50µl per well and the plate was incubated overnight at 4oC.  
Samples were then removed by washing three times with ELISA wash buffer. The detection 
antibody was diluted in 2% BSA/PBS, added to the plate (50µl/well) and incubated at room 
temperature for 4 hours. Detection antibody was removed by washing three times with 
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ELISA wash buffer, then the enzyme streptavidin horseradish peroxidase was added 
(50µl/well) for 1 hour at room temperature. Colour reagent TMB microwell peroxidase was 
added (100µl/well) and colour was allowed to develop. The reaction was stopped using 50µl 
1M sulfuric acid (H2SO4) and absorbance was measured at 450nm in a Versa Max 
microplate reader (Molecular Devices, UK)  
Standard curve analysis was performed using SoftMax pro software and unknown 
concentrations of cytokines in the samples were calculated from the standard curve. 
Flow cytometry 
All cell preparation was done aseptically, and on ice. THP-1 or H357 cells were dissociated 
from the tissue culture plastic with Accutase cell dissociation solution at 37oC. Once lifted, 
medium containing serum was added to inhibit the enzymes. Cells were then transferred to 
sterile tubes and centrifuged at 230 G for 5 minutes. The supernatants were gently removed 
with a pipette and the pellets were re-suspended by gentle flicking of the tubes. 1ml of 
staining solution (1% BSA in sterile Ca2+ and Mg2+ free DPBS) was added and tubes were 
inverted 10 times to evenly distribute the cells. A 10µl sample was taken and mixed 1:1 with 
Trypan blue exclusion dye and cells were counted on a haemocytometer.  
2x106 cells were collected and centrifuged at 230 G for 5 min and re-suspended in 300µl 
staining solution, giving a concentration of 106 cells/150µl. After incubation on ice for 30 
minutes to block non-specific binding, 15µl containing 105 cells was transferred to sterile 
500µl Eppendorf tubes. To each tube, the appropriate amounts of antibody, isotype control 
or staining buffer were added. Tubes were vortexed at a moderate speed and briefly spun 
(~10 seconds) to make sure the cells and antibody were evenly mixed.  
Samples were incubated on ice and in the dark for 30 minutes, following which 400µl 
staining buffer was added to wash any unbound antibody from the cells and centrifuged at 
230 G for 5 minutes. Supernatants were removed and cells were re-suspended in 500µl 
PBS, filtered through a 35 µm cell strainer mesh into sterile polystyrene tubes (Beckton 
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Dickenson, UK) and processed in the BD FACSaria flow cytometer. Data was acquired using 
FACSDiva software (Becton Dickenson) and analysed using WinMDI software (Joseph 
Trotter, Scripps Research Institute, San Diego, USA. 
Mean fluorescence intensity (MFI) was calculated using the following formula: 
 
 −	
			
		  × 100 
 
Table 4: List of antibodies used in flow cytometry 
Antibody Conjugated fluorophore Concentration 
Anti-TLR2 Phycoerythrin 0.25μg/test 
Anti-TLR4 Phycoerythrin 0.25μg/test 
Isotype control Phycoerythrin 0.25μg/test 
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Total RNA isolation by acid guanidinium thiocyanate-phenol-chloroform 
extraction from THP-1 cell line 
(Adapted from161) 
 
Reagents: 
• Guanidinium thiocyanate (4M) 
• Sodium citrate 
• N-laurosarcosine (sarkosyl) (10%) 
• 2-mercaptoethanol 
• Sodium acetate (anhydrous) (2M, pH4.0) 
• Glacial acetic acid 
• Water saturated phenlol 
• 1 –bromo-3-chloropropane 
• Isopropanol (~100%) 
• Ethanol (70%) 
• RNase- and DNAse- free water 
Denaturing solution: 
Stock denaturing solution was prepared by dissolving 25g of guanidium thiocyanate in 
29.3ml of water at 65oC, followed by 1.76ml of 0.75M sodium citrate, pH 7.0, and 2.64ml of 
10% sarkosyl. Denaturing solution was activated before use by addition of 72µl 2-
mercaptoethanol to 10ml of the stock solution.  
2M sodium acetate, pH 4.0 
16.42g of sodium acetate (anhydrous) was added to 35ml of water and 40ml glacial acetic 
acid. pH was adjusted to 4.0 with glacial acetic acid and the final volume was brought to 
100ml with water. 
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Following experiments, culture supernatants were removed from THP-1 cells and 500µl of 
denaturing solution was added directly to the wells. Cells were rested in denaturing solution 
for 1 minute to allow complete lysis and the solution was pipetted up and down 10 times to 
ensure all the lysate was collected. The samples were allowed to sit for 5 minutes before 
being frozen at -20ºC for later analysis. 
To extract the RNA, 50µl of 2M sodium acetate, pH 4.0 was added to the cell lysates and 
mixed thoroughly by inversion. Then, 500µl water saturated phenol was added, mixed by 
inversion, followed by 100µl of 1-bromo-3-chloropropane, and shaken vigorously by hand to 
mix. Samples were cooled on ice for 15 minutes then centrifuged for 20 minutes, 15000g, at 
4oC. 
The upper aqueous phase containing mostly RNA was transferred to an RNAse- and DNAse 
free Eppendorf tube and an equal amount of isopropanol was added to precipitate the RNA. 
Samples were incubated at -20ºC until needed for the next step. 
Samples were centrifuged for 20 minutes, 15000g, at 4oC. The supernatant was discarded 
and the gel-like precipitate (RNA) was retained then dissolved in 300µl of denaturing solution. 
Next, 300µl of isopropanol was added and the samples were incubated at -20ºC for at least 
30 minutes, after which they were centrifuged for at 15000g for 10 minutes at 4oC. The 
supernatant was discarded and the pellet was re-suspended in 500µl of 75% ethanol and 
vortexed for 10 seconds to mix, and then incubated for 15 minutes at room temperature to 
dissolve any residual guanidinium thyocyanate. At this point, samples were stored at -20ºC 
until RNA extraction could be completed.  
Samples were centrifuged for at 15000g for 20 minutes at 4oC, and the supernatant was 
discarded. The pellet was air dried for around 15 minutes in a laminar flow hood at room 
temperature, and then the RNA was dissolved in 15µl of RNAse- and DNAse- free water and 
incubated for 15 minutes at 60oC to ensure complete solubilisation of the RNA. To remove 
any residuial genomic DNA, samples were treated with the DNAse 1 kit (Sigma, UK). To the 
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solublised RNA, 1.5µl of 10x reaction buffer and 1.5µl amplification grade DNase 1 (1 unit / 
µl) were added and samples were left to stand at room temperature for 15 minutes. To stop 
the reaction, 1.5µl stop solution was added to each tube. Samples were then incubated at 
70ºC for a further 10 minutes, then placed on ice ready for reverse transcription. 
Reverse transcription 
RNA quantity was determined using a NanoVue plus (GE Healthcare) spectrophotometer 
and purity was estimated using the A260/A280 ratio.  
0.5µg RNA was added to RNAse and DNAse- free PCR tubes, and made up to a total 
volume of 9µl with water. A master mix of RT buffer (Applied Biosystems) and enzyme (50 
U/µL MultiScribe™ MuLV, Applied Biosystems, UK) was prepared by adding 10µl buffer and 
1µl enzyme per sample to a tube. RNA, water and master mix were added sequentially to 
PCR tubes. Tubes were briefly spun down to pool the ingredients and eliminate any air 
bubbles. The reverse transcription reaction was done by incubating the samples in a thermal 
cycler (Veriti, Applied Biosystems) at 37oC for 60 minutes and stopped by heating to 95oC for 
5 minutes and held at 4oC. The cDNA generated was stored at -20ºC until ready for qRT-
PCR.  
Quantitative real-time polymerase chain reaction (qRT-PCR) 
For all PCR, Power SYBR green PCR master-mix (Applied Biosystems) was used.  
cDNA generated from RNA samples was prepared for qRT-PCR. A master mix containing 
10µl SYBR green, 1.25µl (12.5µmol) forward primer, 1.25µl (12.5µmol) reverse primer and 
2.5µl water per sample was prepared for each assay. 1µl of cDNA was diluted in 4µl of water 
for each test. 15µl of master mix followed by 5µl diluted cDNA was added to the appropriate 
well in a 96 well PCR plate, in duplicate. qRT-PCr was run under the following cycling 
conditions on the Applied Biosystems StepOne Plus  real-time  PCR system:  
• Hold at 95 ºC for 10 minutes 
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• Denauture at 95 ºC for 15 seconds then anneal/extend at 60 ºC for 60 seconds x 40 
cycles. 
Data analysis 
Data was acquired and analysed on the Applied Biosystems StepOne software (Applied 
Biosciences, UK). Human β actin 1 was used as the internal reference gene (housekeeping 
gene), and non-polarised (PMA treated) macrophages were used as calibrator samples. 
Differences in gene expression levels were calculated relative to the calibrator sample using 
the  ∆∆ Ct method. 
 
Statistical analyses 
 
For comparison between two independent treatment groups, tests for differences were analysed using 
analysed using Student’s t-test (Figure  3-2, Error! Reference source not found., Figure 4-3 to 4-5, 
Figure  5-3 C and Figure 5-4 – 5-8) if the data were parametric, or Mann Whitney U test if data were non-
parametric (Error! Reference source not found. C – EcLPS). In experiments where more than two groups of 
treatments were being tested, a one-way analysis of variance (if the data were parametric) with the Holm-
with the Holm-Sidak method for all pairwise comparison procedure to test for differences between 
between groups (Figure  3-, Figure  4- to 4-12,  
 
 
 
 
 
 
 
Figure  5-4 and Figure  5-12), or the Kruskall-Wallis analysis of varience if the data was non-
parametric (Figure  3-a – Pam3csk4) were used. Results were considered significant if the p 
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Chapter 3 - Optimisation of an M1/M2 macrophage polarisation 
model using the cell line THP-1 
 
Macrophages perform specific functions dependant on their location, origin, and factors 
encountered in the microenvironment. Macrophages differentiate from peripheral blood 
monocytes and (broadly speaking) undergo two types of activation; classical and alternative. 
In vivo, classically activated macrophages (M1) are polarized by granulocyte macrophage-
colony stimulating factor (GM-CSF) and activated by IFNγ 31,33. Alternatively activated 
macrophages (M2), are polarized by M-CSF 31–33 and can be further divided into three 
subsets: M2a, M2b and M2c. M2a are activated by IL-4, IL-13 or both, M2b are activated by 
complement and TLR ligation, and M2c are activated by IL-10 32,68.  M2 macrophages exhibit 
anti-inflammatory properties and express regulatory cytokines, IL-10, IL-1Ra and TGF-β. M1 
type macrophages express high levels of pro-inflammatory cytokines, TNFα, IL-1β , IL-18, 
IL-6, IL-12 and IL-23 32.  
Macrophages in the oral mucosa  
The ratio of M1 to M2 macrophages in the oral mucosa may vary between health and 
disease. Under homeostatic conditions, the predominant macrophage population is likely to 
be regulatory; mucosal macrophages take on an M2 phenotype as a means of controlling 
aberrant inflammation to commensal bacteria and food antigens. During disease, however, 
the immune status of the oral mucosal tissues is prone to change. The cytokine milieu 
present in periodontal lesions is both Th1 and Th2 related, with more recent evidence 
suggesting that Th17 cytokines are also involved 162,163.  
Given the variety of M1 and M2 polarising cytokines present in lesions, macrophages may 
become polarised to an M1 or M2 phenotype, or both, dependant on disease state (i.e. 
health versus disease, acute versus chronic).  
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Macrophage dysfunction in oral disease 
Disruption in macrophage number and function may play a more important role in driving 
disease than pathogenic causes alone. Whilst a known aetiological agent in periodontitis 4,69,  
the presence of pathogenic bacterium Porphyromonas gingivalis in the oral microflora does 
not presuppose disease 164,165. Porphyromonas gingivalis colonise epithelial cells in healthy 
and periodontally diseased patients 166, suggesting that a dysfunctional immune response 
plays a key role in disease progression. Investigations indicating that macrophages remain 
in an un-activated state in periodontal lesions167 credits this theory. Whilst rapid inflammation 
is seen in response to ceasing oral hygiene routines 165 there is no change in macrophage 
number between healthy gingival tissues and periodontitis-associated tissues 168. In oral 
squamous cell carcinoma (OSCC), whilst the infiltrating macrophage count predicts poor 
prognosis 169, these macrophages develop a pro-tumoural, M2 like phenotype 150 which also 
correlates with poor prognosis 131,146. These findings implicate macrophage dysfunction - 
rather than number - is integral to disease progression.   
Despite the likelihood that M2 macrophages are present in both oral health and disease, 
their interactions with - and responses to - pathogenic oral bacteria, such as P. gingivalis are 
yet to be investigated. 
Macrophages in vitro: Generation M1 and M2  
Investigation of macrophage/oral pathogen interactions requires a robust in vitro model of 
M1 and M2 macrophages. In vivo, several factors have been shown to induce macrophage 
differentiation from monocytes with polarization into distinct phenotypes. Numerous methods 
have been developed using human peripheral blood monocytes, most using M-CSF to 
generate M2 and GM-CSF to generate M1 170. Other methods have used combinations of IL-
1β , TNF-alpha or LPS to generate M1, and IL-4, IL-13, or both, to generate M2 171. 
Treatment with combinations of these factors up-regulates expression of distinctive M1 or 
M2 markers. Treatment with IFNγ leads to up-regulation of typical M1 receptors CD80 and 
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CD64 (FcgammaR1) 172,173. IL-4 treatment up-regulates CD36174 expression and activation of 
STAT6 175 and down-regulates CD14 172,173, iNOS 174 and CD163 176, and  inhibits phagocytic 
capacity 177. Macrophages polarised with IL-10 up-regulate surface markers CD163 and 
CD16 172,173. Despite being the gold standard in human monocyte and macrophage research, 
primary cells are difficult to obtain and often yield low numbers. Immortalised cell lines can 
be used instead, although different researchers use different concentrations and 
combinations of factors to polarise monocytes into macrophages; there is no consensus on 
how to generate an effective M1/M2 model using cell lines. Among the variety in 
methodology there are similarities, particularly in the pro-monocytic cell line, THP-1 (see 
Table 3-1). Established by Tsuchiya et al. in 1980 178 from an acute myeloid leukaemia, 
THP-1 cells have been shown to better reflect the behaviour of primary cells than other 
monocytic cell lines 179 and can be differentiated to monocytes, macrophages or dendritic 
cells 179–181 Thus, the objective of this research was to establish a robust, reproducible model 
of M1 and M2 macrophage polarisation using THP-1, so that their interactions with 
pathogenic oral bacteria could be investigated.  
 As well as the human THP-1 cell line, many studies have used mouse primary cells or cell 
lines to generate M1 and M2 like macrophages, characterised by their expression of 
arginase (M2) and NOS (M1), and Ym and FIZZ-1. Whilst expression of iNOS and ARG-1 
has been demonstrated in human cells 182,183 their validity as M1/M2 markers in humans 
remains a bone of contention 184,185. 
In the present study, a series of experiments were designed to determine the method of 
generating M1 and M2 macrophages in vitro the displayed the most similar cytokine profile 
to primary M1 and M2 macrophages. Using the literature as a guide, the M1/M2 polarising 
properties of several known macrophage differentiation factors (PMA, vitamin D3, IL-13, IL-4 
and IFNγ) were tested. 
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Table  3-1: Methods of M1 and M2 polarisation using THP-1 cells from previously 
published research 
Author Differentiation protocol Measured effects 
 
Caras (2011)151 
 
30 ng/ml PMA for 6 
hours, then: 
 
M1: PMA and 10 ng/ml 
LPS + 5 ng/ml IFNγ for 
66 hours 
 
M2: 25 ng/ml IL-4 + 25 
ng/ml IL-13 for 66 hours 
 
Cells were cultured for a 
further 24 hours in 
complete medium 
 
M1: Higher levels of TNFα, IL-6 and 
IL-1Ra  
 
M2: Lower levels of TNFα, 
comparable levels of IL-6, and 
higher levels of IL-1Ra 
 
(vs. PMA alone) 
 
Dabelic (2006)186  
 
10−7 M PMA for 48 
hours.  
 
Up regulation of Galectin-3 
expression 
 
Daigneault (2010)187 
 
200nM PMA for 3 days, 
followed by a rest period 
of 5 days  
 
Generated macrophages closely 
resembling primary bone marrow 
derived macrophages (BMDM; 
assessed by morphology, adherence 
and CD14 expression), 
 
Isa (2011)188 
 
Monocytes: 100 ng/ml 
PMA* for 72 hours 
 
M2 monocytes: IL-13 15 
ng/ml and 1µM 
rosiglitazone for 72 hours 
 
M2 MΦ: 100 ng/ml PMA 
for 6 hours, followed by 
addition of 15 ng/ml IL-13 
and 1µM rosiglitazone for 
66 hours 
 
M2 macrophages up-regulated  
CD206 and IL-1Ra expression. M2 
Macrophages more sensitive to 
apoptosis induced by oxLDL than 
monocytes 
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MacKinnon(2008)189  
 
100 ng/ml PMA for 24 
hours 
 
10 ng/ml IL-4 for 24 
hours  
 
 
100 U/ml IFN-γ/100 ng/ml 
LPS for 24 hours 
 
 
Up-regulation of Galectin-3 and 
CD98 
 
Up-regulation of CD206 and 
galectin-3 expression 
 
Inhibition of CD206 and galectin-3 
expression 
 
 
McLaren (2010)190  
 
160nM PMA for 24 
hours100 ng/ml 
 
Monocyte to macrophage 
differentiation  
 
Ribbens (2000)191  
 
4 ng/ml Vitamin D3 for 48 
hours  
 
Allows THP-1 responsiveness to 
stimulation 
 
Smythies (2010)192  
 
4F, apoA-I, or vehicle for 
7 days 
 
Down-regulates: HLA-DR, CD86, 
CD11b, CD11c, CD14, TLR-4, 
CD49d* CD32 , LPS-induced mRNA 
of MCP-1, MIP-1, RANTES, IL-6, 
TNFα, monocyte adhesion to human 
endothelial cells, transendothelial 
migration and phagocytosis of 
dextran-FITC beads  
 
Up-regulates IL-10  
 
Spencer (2010)193  
 
M1: 20 ng/ml LPS + 20 
ng/ml IFNγ overnight in 
serum free media 
 
M2: 5 nM TPA in PBS for 
5 min, then: 
 
20 ng/ml IL-4 (M2a) 
20 ng/ml IL-10 (M2c) 
overnight 
 
M1: Higher levels of IL-1 and IL-12, 
lower levels of IL-10 
 
M2: Lower levels of IL-1 and IL-12, 
higher levels of IL-10 
 
Measured mRNA 
 
Tjiu (2009)194  
320nM PMA for 24 hours 
20 ng/ml 
 
Up- regulation of CD206 and CD204 
expression 
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Vey (1992)195  
 
Vitamin D3 (4 ng/ml) or 
IFNγ (500U/ml) for 48 
hours. 
 
TNFα , IL-1β and IL-6 production 
was evident in IFNγ stimulated cells, 
but not in Vitamin D3 stimulated 
cells.  
 
IL-1β co-cultured with activated and 
fixed T cells and Vitamin D3 treated 
THP-1 cells up-regulated  their 
cytokine production; IFNγ treated 
THP-1 did not.  
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Results 
PMA as a macrophage differentiating factor: PMA induces THP-1 
adherence , a marker of monocyte – macrophage differentiation. 
PMA is an established macrophage differentiation factor in THP-1 cells, but is also a potent 
macrophage activator.  In a study by Daigneault et al (2010)187  THP-1-cells were treated 
with 200nM PMA for 3 days, followed by a rest period of 5 days to generate macrophages 
closely resembling primary bone marrow derived macrophages (BMDM; assessed by 
morphology, adherence and CD14 expression), . It is yet to be established whether PMA 
treatment leads to the generation of macrophages displaying M1 or M2 profiles. To 
determine whether this protocol would lead to a differential expression of M1 and M2 
markers in our model, and allow enough time for recovery from PMA activation, THP-1 cells 
were differentiated with 200nM PMA for 3 days and left for a series of resting periods of 0, 1, 
2, 3, 4 and 5 days (Figure  3-1). Culture supernatant levels of TNFα, an M1 marker, in 
response to P. gingivalis LPS (A), heat killed P. gingivalis (B), E. coli strain  K12 (C) and 
synthetic TLR2 ligand Pam3csk (D) were assayed by ELISA. Effective concentrations of 
stimulatory PAMPs were  determined by dose/response experiments (data not shown) and 
was in accordance with current literature.  
As resting time increased, TNFα production decreased in response to all stimuli. 
Background levels of TNFα were elevated at day 0, but had returned to negligible levels by 
day 1.  A resting period of 1 day allows cells enough time to recover from PMA activation, 
but still exhibit a high level of TNFα production in response to stimulation with PAMPs 
(Figure 3-1). Following PMA treatment, THP-1 cells became strongly adherent to the culture 
plates. At a 200nM concentration of PMA, and at 1 day post treatment, cell adherence and 
high TNFa production indicate that cells have adopted an M1-like phenotype. However, as 
resting time increased, TNFa production decreased in response to stimulus, and reduced 
TNFa production is associated with M2 polarisation. Thus, PMA treatment generated an 
adherent macrophage population, but M1 or M2 phenotypes were not clear.  
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Figure  3-1: A resting period of one day is sufficient for THP-1 cells to recover from PMA 
stimulation, but still exhibit a pro-inflammatory profile in response to PAMPs. 25 ng/ml5 
ng/mlData are expressed as the mean of triplicate samples in one experiment ± standard 
deviation. 
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Vitamin D3 as a macrophage differentiating factor: Vitamin D3 treatment 
does not induce cell adherence, and induces a cytokine profile unlike M1 
or M2 macrophages. 
 
Like PMA, vitamin D3 is a commonly used macrophage differentiation factor. Because of its 
purported anti-inflammatory properties, it was hypothesised that vitamin D3  mediated 
differentiation might generate an M2- like population of macrophages. To test this in the 
present study, THP-1 cells were treated with vitamin 10nM D3 for 4 days to differentiate 
them into macrophages. To keep differentiation periods the same for both PMA and vitamin 
D3 treatment (thus keeping the age and passage number of the cells equal), the 
concentration of PMA was reduced to 25nM and the differentiation period was extended to 3 
days. Following differentiation, cells were washed 3 times in PBS and then stimulated with 1 
µg/ml P. gingivalis LPS for 24 hours. Levels of phenotypic markers TNFα, IL-12, IL-6, IL-1β 
(M1), CCL18 (M2) were measured in the culture supernatant (Figure  3-2).  
1 µg/mlIn response to P. gingivalis LPS, PMA treated macrophages produced higher levels 
of TNFα compared with vitamin D3 treated cells, however, the difference in TNFα production 
between cell types was minimal (Figure  3-2 A, p=0.02).  Conversely, Vitamin D3 treated 
THP-1 cells expressed markedly higher levels of M1 associated cytokines IL-1β (Figure  3-2 
B, p<0.001) and IL-6 (Figure  3-2 C, p<0.001) in response to P. gingivalis LPS compared to 
PMA treated cells. IL-12 (p70 subunit) and CCL18 were not detected in any of the culture 
supernatants (data not shown). These data suggest that the PMA/Vitamin D3 model of 
M1/M2 polarisation might not accurately reflect the behaviour of M1 and M2 macrophages in 
vivo. 
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Figure  3-2: PMA or Vitamin D3 treated cells do not display M1 and M2 profiles. 
THP-1 cells were treated with PMA or Vitamin D3, and then stimulated with P. gingivalis 
LPS for 24 hours. Cell free supernatants were assayed for TNFα, IL-1β and IL-6 by 
ELISA. Data represent means of 3 independent experiments performed in triplicate 
(n=3). Tests for statistically significant differences were performed using one way 
ANOVA. 
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Polarisation of THP-1 cells into M1 and M2 like phenotypes using Th1 
and Th2 cytokines 
The present data suggest that treatment of THP-1 cells with Vitamin D3 does not yield 
effective M2 like macrophages. Previous studies using the THP-1 cell line to generate M2 
like macrophages have commonly used TH2 cytokines IL-4 and IL-13, either alone or in 
combination189,194. In order to establish whether further polarisation along M2 pathways using 
TH2 cytokines yields a more characteristic M2 cytokine profile, experiments were conducted 
to assess responses of IL-4/13 treated THP-1 cells to LPS stimulation, based on a method 
adapted from Tjiu et al (2009)160: 
To generate M2 (i): 15 ng/ml15 ng/ml5 ng/ml IL-13 for 72 hours, followed by 100 ng/ml PMA 
for 72 hours, with 24 hours rest 
To generate M2 (ii): 15 ng/ml15 ng/ml5 ng/ml IL-4 for 72 hours, followed by 100 ng/ml PMA 
for 72 hours, with 24 hours rest  
To generate M1 (i): 100 ng/ml PMA for 72 hours, with 24 hour rest  
THP-1 cells were incubated with PMA , IL-4 or 13 for 3 days, followed by PMA for 3 days to 
generate M1 and M2 (i) and M2 (ii), respectively. Following a 24 hour rest period, cells were 
stimulated with 1µg/ml P. gingivalis LPS or 1µg/ml E. coli LPS, or were incubated with media 
alone as a negative control. 
No difference was observed in TNFα production in response to P. gingivalis or E. coli LPS 
between IL-4 and IL-13 polarised cells (Figure  3-3). PMA treated cells produced the highest 
levels of TNFα in response to both LPS, however, background levels of TNFα were also 
elevated in un-stimulated PMA treated cells (Figure  3-3). It is possible that greater up-
regulation of TNFα was due to direct activation by PMA, rather than in response to PAMPs.  
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Figure  3-3 : TNFα expression in PMA, IL-4 or IL-13 treated THP-1 cells. THP-1 cells were incubated with PMA for 3 days, or IL-
4 or 13 for 3 days, followed by PMA for 3 days. Following a 24 hour rest period, cells were stimulated with 1ug/ml P. gingivalis LPS 
or 1ug/ml E. coli LPS, or were incubated with media alone as a negative control. Data are expressed as the mean of triplicate 
samples within one experiment ± standard deviation.   
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Treatment of THP-1 with PMA and IFNγ or IL-4 generates cell 
populations exhibiting a differential pro-inflammatory cytokine profile 
According to Borthwick et al. 2011 (un-published data), and in conformity with other 
published material on THP-1 polarisation 172,173,194,195 addition of IFNγ to PMA treated THP-1 
further polarises cells into an M1 like phenotype. To test this, experiments were conducted to 
determine if incubation with IFNγ generated a more robust M1 model. As there was a lack of 
discrepancy between IL-4 and IL-13 treated cells, IL-4 was used in subsequent experiments. 
Additionally, the order in which IL-4 and PMA were added was reversed, as previous studies 
have shown that IL-4 receptor expression is down-regulated during monocyte – macrophage 
differentiation 196. 
THP-1 cells were incubated with 5 ng/ml PMA for 6 hours to initiate cellular adhesion and 
monocyte/macrophage differentiation. To generate a population of non-polarised 
macrophages, PMA was removed and refreshed with media containing 5 ng/ml PMA. Cells 
were cultured for a further 18 hours. To generate M1 and M2 like macrophages, after 6 
hours initial PMA treatment, cells were incubated with 20 ng/ml IFNγ or 20 ng/ml IL-4, plus 5 
ng/ml PMA, respectively. After a total of 24 hours, the polarisation process was complete 
and cells were ready for use in further experiments (see  Figure 3-4).  
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Figure  3-4: Schematic representation of the differentiation protocol for THP-1 polarisation.  
 
M1 and M2 macrophages have been characterised according to their inflammatory cytokine 
profiles. M1 macrophages classically express high levels of TNFα, IL-12 and IL-23, whereas 
M2 typically produce anti-inflammatory cytokines IL-10, TGF-β and IL-1Ra in response to 
LPS/TLR interactions 31. To determine whether IFNγ macrophages and IL-4 macrophages 
took on differential cytokine profiles following polarisation, polarised cells were incubated for 
24 hours with 1µg/ml of either P. gingivalis LPS (purported TLR2 ligand) or E. coli LPS 
(TLR4), see Error! Reference source not found. for schematic representation. Pro-
inflammatory cytokines TNFα, IL-1β and IL-6 were measured by ELISA. Anti-inflammatory 
cytokines/chemokines CCL18, IL-1Ra and IL-10, and M1 associated cytokine IL-12p70 were 
also measured but were not detectable at protein level in the supernatant. 
In response to P. gingivalis and E. coli LPS, the expression of M1 associated cytokines 
TNFα, IL-1β and IL-6 was higher in IFNγ treated macrophages than PMA and IL-4 treated 
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macrophages (Error! Reference source not found.5: A, B and C, p=0.01 , p=0.014,  
p=0.006, respectively). As previously described 197, up-regulation of TNFα, IL-1β and IL-6 
was induced to a greater extent by E. coli LPS; stimulation of macrophages in all polarisation 
states by E. coli LPS resulted in higher inflammatory cytokine production than P. gingivalis 
LPS. Next, the expression level of M2 associated cytokines IL-10 and TGF-β were 
measured by qRT-PCR. Briefly, cells were polarised with IFNγ or IL-4, then stimulated with P. 
gingivalis LPS for 6 hours. Un-stimulated cells (no LPS) served as negative controls.  
Culture supernatant was removed and cells were lysed for RNA extraction (see methods 
chapter for details and primer sequences). Relative gene expression levels were calculated 
using the ∆∆Ct method, normalised to housekeeping gene, β-actin and compared with un-
polarised, MØ macrophages.  THP-1 treated with IL-4 expressed higher levels of IL-10 and 
TGF-β mRNA than IFNγ treated cells in response to P. gingivalis LPS. Basal levels of both 
cytokines however were similar between M1 and M2 macrophages (Figure 3-6, A and B). At 
24 hours stimulation, M2 still expressed higher levels of TGF-b, but IL-10 reached similar 
levels (Figure 3-6 C). 
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Figure  3-5: IFNγ and IL-4 differentiate macrophages with distinct M1 and M2 inflammatory cytokine 
profiles 
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Figure  3-6: Expression levels of M2 markers IL-10 and TGF-β are higher IL-4 treated than 
IFNγ treated macrophages. Gene expression levels of IL-10 (A) and TGF-b (B) were measured 
in M1 and M2 macrophages stimulated with P. gingivalis LPS for 6 hours. Unstimulated cells 
served as negative controls. IL-10 and TGF-β was also measured in unstimulated cells at 24 
hours. 
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and IL-6 were higher in IFNγ macrophages than in IL-4 or PMA macrophages (Figure  3-7). 
There was no difference in TNFα or IL-1β production between PMA and IL-4 macrophages 
in response to Pam3csk4, but PMA macrophages produced higher levels of IL-6 compared 
with IL-4 macrophages, although this did not reach statistical significance.  Interestingly, 
unlike LPS, there was no difference in TNFα production induced by pam3csk4 between any 
of the cell types (Figure 3-7, summarised in table 3-2). Furthermore, activation of TLR2 by 
Pam3csk4 induced far higher levels of inflammatory cytokines than P. gingivalis LPS, 
suggesting that it is not differential utilization of TLR2 that is responsible for discrepancy 
between P. gingivalis LPS and E. coli LPS.  
Table  3-2: Summary of cell-type specific cytokine production in response to Pam3csk4. Crosses indicate 
levels of expression, +++ being high and + being low. 
 IFNγ macrophages IL-4 macrophages PMA macrophages 
TNFα +++ +++ +++ 
IL-1β +++ + + 
IL-6 +++ + ++ 
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Figure  3-7: TNFα, IL-1β and IL-6 production in response to P. gingivalis LPS, E. coli LPS and Pam3csk4. 
Data are expressed as the mean ± standard deviation from three independent experiments. *NS = no significant 
difference. 
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Discussion 
There is no established protocol for differentiation/polarisation of THP-1 into M1 or M2 like 
macrophages. Previous work in our laboratory had used PMA and Vitamin D3 to generate 
M1 and M2 like THP-1 macrophages, respectively. PMA and Vitamin D3 are commonly used 
differentiation factors, but to date there are no published studies which have used Vitamin 
D3 to generate alternative macrophages. Although Daigneault et al.  187  assessed ability of 
Vitamin D3 to generate a population of cells closely resembling primary monocyte derived 
macrophages, the group concluded that PMA was a more effective method of macrophage 
differentiation than Vitamin D3, and Vitamin D3 treated cells were excluded from further 
analysis. The study did not assess capacity of Vitamin D3 to differentiate THP-1 into an M2 
like phenotype.  
Vitamin D3 signals through the Vitamin D receptor in the nucleus and activates the PI3K 
pathway 198,199. PI3K is associated with alternative macrophage polarisation 189 and 
negatively regulates M1 markers, iNOS 200 and IL-12B 201. However, Vitamin D3 has also 
been shown to down-regulate M2 related cytokine IL-10 expression in THP-1 cells  202. 
Treatment of THP-1 with Vitamin D3 generated a population of cells which were highly 
proliferative and non-adherent. PMA treated THP-1, in contrast, generated a population of 
cells which were non-proliferative and adherent to cell culture plastic. Percentage viability 
was lower in vitamin D3 treated than PMA treated cells.  
At all time points, TNFα production was higher in Vitamin D3 treated cells than PMA treated 
cells, at baseline and in response to P. gingivalis LPS. A longer M2 differentiation period led 
to a reduction in TNFα, however, it remained higher than that of M1 cells, even after 7 days.  
This decrease could be a result of increased proliferation of  vitamin D3 treated cells 
observed at the end of the experiment. PMA treated  cell number did not increase over the 
experimental period.    The higher level of cell death in vitamin D3 treated than PMA treated 
cells increased with differentiation time. It is possible that TNFα was released from 
intracellular stores upon cell death in the Vitamin D3 treated cells, or that it was up-regulated 
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in response to apoptotic or necrotic cell debris. Neither IL-12 nor CCL18 were detected in 
supernatants from any cell types. Faulty antibodies/ELISA techniques were ruled out as 
standard curve worked well.  Previous studies 203 have shown that IL-12 is up-regulated in 
response to E. coli LPS, so it may be that P. gingivalis LPS (TLR2 ligand) does not induce 
IL-12 expression. However, none of the cell types replicated this.  
The inflammatory cytokine profiles of PMA and vitamin D3 treated cells suggest that these 
treatments do not yield definitive M1 and M2 like macrophage populations. A 2012 study of 
the polarising capacity of vitamin D3 revealed that the compound did not induce expression 
of either M1 or M2 markers 204.  In the present study, vitamin D3 treatment resulted in 
expression of M1 characteristic cytokines, but was rejected from further use in polarisation 
protocols as  the cells were non-adherent (adherence is a marker of macrophage 
differentiation) and there was higher level of cell death. Whilst PMA had undesirable 
activatory properties, these had returned to baseline levels after 24 hours. Thus, PMA was 
chosen for use in further polarisation experiments. 
To establish whether IL-4, IL-13, or both could further polarise cells to an M2 phenotype, 
THP-1 cells were incubated with 20 ng/ml of IL-4 or IL-13 for 72 hours, followed by 100 
ng/ml PMA for a further 72 hours. Cells were washed to remove PMA and allowed to rest for 
24 hours before stimulation with a range of PAMPs (Figure  3-3). There was no difference in 
TNFα production in response to P. gingivalis or E. coli LPS between IL-4 and IL-13 polarised 
cells. PMA treated cells produced highest levels of TNFα in response to range of PAMPs 
however; background levels of TNFα were also elevated in un-stimulated PMA treated cells. 
It is possible that greater up-regulation of TNFα was due to direct activation by PMA, rather 
than in response to PAMPs.  
It is widely accepted that IFNγ primes macrophages to take on pro-inflammatory M1 like 
characteristics 170. Thus, we wanted to see if treatment with IFNγ would generate stronger 
M1 characteristics i.e. higher levels of TNFα, IL-1β and IL-6.  In order to generate M1 like 
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macrophages from THP-1, cells were incubated with 25 ng/ml PMA for 6 hours, followed by 
PMA + 20 ng/ml IFNγ for a further 18 hours. The PMA concentration was lowered from 100 
ng/ml to 25 ng/ml, as 100 ng/ml appeared to directly activate cells (Figure  3-3, PMA control) 
in accordance with previously published data 205. As there was no difference in TNFα 
production between IL-4 and IL-13 treated cells, IL-4 was used for all subsequent 
experiments to generate M2 like cells. Cells treated with 25 ng/ml PMA were included as a 
negative control for polarisation. In a previous study by Caras et al., PMA/IFNγ treatment 
period was increased from 24 hours to 72 hours because their cells became unstable and 
were dis-adhered by simply washing 151. However, in our model, THP-1 + PMA/cytokine 
were strongly adhered. A resting period following PMA treatment was not needed as 
baseline production of cytokines in un-stimulated cells was low. 
TNFα, IL-6 and IL-1β production were highest in response to Pam3csk4, followed by E. coli 
LPS, with P. gingivalis LPS inducing lowest levels of cytokines in all cell types.  In line with 
data published elsewhere 197,206–209, E. coli LPS consistently induced cytokine production in 
all cell types to a higher level than P. gingivalis LPS. This property of P. gingivalis LPS is 
thought to be a mechanism by which it evades host immune response 210. 
IFNγ treated macrophages were consistently the highest responders to all stimuli, with IL-4 
and PMA macrophages displaying similar cytokine profiles. Interesting results were obtained 
from response of different cell types to Pam3csk4; PMA, IFNγ and IL-4 macrophages 
displayed differential production of IL-6 and IL-1β in response to Pam3csk4, but this 
discrepancy between cell types was lost with respect to TNFα (Figure  3-7). 
This lack of discrepancy in TNFα production could either be down to high specificity of 
Pam3csk4 for TLR2 masking any subtle differences between cell types, or that IFNγ and IL-
4 macrophages display differential responses to TLR4 ligation, but not TLR2.  Differential 
cytokine profiles between cell types in response to TLR4 ligand E. coli LPS are obvious. 
Although levels of cytokine production in response to P. gingivalis LPS were lower than that 
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of E. coli LPS, pattern of expression was similar. Porphyromonas gingivalis LPS is purported 
to be a TLR2 ligand 207,211,212, but this is still a contentious issue. Whether P. gingivalis LPS 
utilises TLR2 or TLR4 appears to depend on method of LPS purification and culture 
temperature, among other things. 91,92,163,213. Investigation into whether lack of discrepancy in 
TNFα production between cell types in response to Pam3csk4 is TLR2 or stimulus specific is 
needed.   
IFNγ and PMA treated macrophages display similar IL-6 up-regulation in response to 
Pam3csk4, whereas IL-4 macrophages produce very little. IL-6 production is similar between 
IFNγ and PMA macrophages (with very little IL-6 produced by IL-4 macrophages), whereas 
IL-1β production is similar in IL-4 and PMA macrophages (with very little IL-1β production in 
IFNγ macrophages). This could be indicative of differential utilization of TNFα, IL-1β and IL-6 
pathways in response to TLR2 activation between cell types.  
Monocytes/macrophages derived from THP-1 cells do not express IL-10 at the protein level 
in response to LPS. . Barksby et al (2009) reported that IL-10 mRNA is up-regulated in THP-
1 cells in response to P. gingivalis LPS 214. It is possible that in THP-1, IL-10 mRNA is 
synthesized de novo in response to stimuli, but not secreted in protein form. This would 
suggest that there is a difference in post translational processing of IL-10 in THP-1 and 
primary cells. Indeed, data from the present study reveal that IL-10 and TGF-β is expressed 
at the mRNA level, and that this expression is higher in IL-4 treated M2 macrophages than in 
IFNγ treated M1 macrophages(Figure 3-6).   
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Chapter 4 - Modulation of Macrophage responses by 
Porphyromonas gingivalis LPS.  
Introduction 
Chronic inflammation can arise when the immune system fails to clear initial infection by 
invading bacteria and becomes dysregulated. Such is the case in the oral inflammatory 
condition, periodontitis. Porphyromonas gingivalis is a well-known periodontal pathogen that 
invades epithelial cells and can spread throughout the epithelium to underlying tissues, 
where it evades recognition by immune cells 74,81,215. In fact, P. gingivalis had evolved 
several mechanisms to avoid immune recognition, thus promoting its survival and 
dissemination, and characteristics permissive to developing chronic inflammation 210. One 
such evasive strategy, once it has penetrated the epithelial barrier, involves P. gingivalis 
attaching to erythrocytes via complement receptor 1 and circulating through the blood 
stream216. The bacterium thereby translocates to sites distant from the oral mucosa where it 
plays a role in development of chronic inflammation outside of the oral cavity. Indeed, P. 
gingivalis has been isolated from atheromatous plaque 111,217, and has been shown to 
enhance uptake of oxidised low density lipoprotein (LDL) by macrophages and induce foam 
cell formation in vitro 218. With regard to epithelial cell invasion, P. gingivalis has been shown 
to preferentially colonise and invade oral squamous carcinoma cells over normal, healthy 
cells121,219,220, and has been isolated from OSCC tumours 119. Like periodontitis, OSCC is 
associated with chronic inflammation and infiltration of macrophages131,146,147,169,221,222. Thus, 
under a variety of pathological circumstances, P. gingivalis and its associated virulence 
factors - such as LPS - interact with macrophages at varying stages of 
activation/differentiation and modulate their behaviour. Infection of macrophages with other 
intracellular bacteria, such as Listeria monocytogenes,  interrupts the interferon gamma 
signalling pathway so that macrophages cannot completely polarise to an M1 phenotype by 
interfering with STAT and its association with its transcriptional co activators 223. The effect of 
P. gingivalis LPS presence during macrophage polarisation, however, is yet to be 
characterised. 
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Porphyromonas gingivalis signalling pathways 
P. gingivalis LPS is renowned for its unusual properties; it is well established that  it has 
lower endotoxin activity than that of E. coli LPS, which is thought to be down to structural 
differences in the lipid A component 89,224,225 and a differential use of TLR signalling 
pathways207. TLR2 and TLR4 share a common signalling pathway (MyD88/MAPK) to 
regulate expression of inflammatory cytokines in response to LPS. In response to activation 
by their cognate ligands, TLR2 (dimerised with either TLR1 or 6) or TLR4 recruit the adapter 
molecule MyD88 via TRIF-related adapter molecule (TRAM) and TIR domain-containing 
adapter protein (TIRAP). MyD88 in turn activates IL-1 receptor-associated kinases (IRAKs), 
required for NFκB activation, via TNF receptor-associated factor 6 (TRAF6). TRAF6 
activates the TGF-β -activated kinase 1/ TAK1-binding protein 2/ TAK1-binding protein 3 
(TAK1/TAB2/TAB3) complex, which then activates the inhibitor of NFκB (IκB) kinase 
complex (IKKα, IKKβ and NEMO). The IκB complex phosphorylates IκB itself, leading to the 
release of NFκB from its inhibitor and its translocation to the nucleus226. In the nucleus, 
NFκB  induces the transcription of inflammatory cytokines via a raft of nuclear proteins; 
C/EBPδ, IκBζ, IκB-NS and Zc3h12a regulate IL-6 expression, AFT3 regulates IL-6 and IL-
12p40 expression, and tristeraprolin (TTP) regulates TNFα  expression226.  
TLR4 is unique in that it can also utilise MyD88 independent signalling pathways in response 
to ligation by LPS227. Cells lacking MyD88 do not produce inflammatory cytokines, rather 
they up-regulate production of chemokine CXCL10 and type I interferons (IFNα and IFNβ)227. 
In this pathway, ligation of TLR4 leads to the recruitment of TRIF. TRIF activates IRF3 (and 
later NFκB) via recruitment of TRAF3 (and TAK1 activation). Activation of IRF3 via 
association with TRAF family member-associated NFκB activator (TANK), TANK binding 
kinase 1 (TBK1) and inducible IKK (IKKi) leads to downstream induction of type I 
interferons228. In TLR4 signalling, TRAF3 is incorporated into the MyD88 complex where it is 
degraded by cIAP1 and cIAP2, inhibiting the MyD88 pathway (thus inflammatory cytokine 
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production), whilst leaving the type I interferon pathway active229 (see Figure  4-3 for 
summary) 
  
Figure  4-1: Schematic representation of MyD88 dependent and independent signalling pathways via TLR 
signalling 
 
Whether P. gingivalis LPS signals through TLR2 or TLR4 remains a contentious issue. 
Porphyromonas gingivalis undeniably utilises either TLR2 or TLR4 because TLR2/4 double 
knock-out cells from mouse bone marrow do not respond to P. gingivalis LPS213. Many 
studies have shown P. gingivalis LPS to signal via TLR296,203,230–235, including one using 
C3H/HeJ mice (a mutant strain that are defective in TLR4), reporting that whilst these mice 
had a defective response to E. coli LPS, they retained the capacity to respond to P. 
gingivalis LPS236, indicating that P. gingivalis LPS utilised TLR2. It has also been reported 
that P. gingivalis LPS signals through a TLR1/2 heterodimer, and that CD14 and LBP must 
also be available234,237. Conversely, many other studies have reported that P. gingivalis LPS 
signals through TLR491,209,238–240. Several reasons for this discrepancy in TLR utilisation by P. 
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gingivalis LPS have been put forward, including LPS purification methods95, with some 
groups claiming that purified P. gingivalis LPS signals through TLR2 , whereas live P. 
gingivalis signals through TLR2 or TLR4241. A further study shows that P. gingivalis LPS 
signals through a combination of TLR2 and intracellular receptor, TLR7242. Finally, Darveau 
et al (2004) suggest that P. gingivalis LPS signals through both TLR2 and TLR4243. A 
consensus is yet to be reached. Thus, two objectives were generated for this study: 
1) Determination of effects of P. gingivalis LPS during the macrophage polarisation 
process on cytokine expression in response to subsequent LPS stimulation 
 
2) Confirmation of the TLR utilised in our model system.  
To do this, macrophages were polarised according to the protocol established in chapter 3 
(Error! Reference source not found.) in the presence or absence of LPS (P gingivalis  or E. 
coli), at doses of 1 ng/ml or 1 µg/ml. Following polarisation, culture media was removed and 
cells were washed 3 times in PBS. Fresh media was added containing either 1 µg/ml 
P.gingivalis or E. coli LPS to activate the macrophages.  Media alone (no LPS) served as a 
negative control (see  Figure 4-11 for schematic representation). After 24 hours incubation, 
cell free supernatants were harvested and stored at -20ºC until assay for TNFα, IL-1β and 
IL-6 by ELISA. 
 
 
81 
 
 
Figure  4-2: Schematic representation of experimental protocol for polarising macrophages in the 
presence of LPS 
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Results 
Effects of LPS on cytokine production during differentiation of non-polarised, PMA 
differentiated macrophages (Mᴓ) 
 
Firstly, the polarisation of macrophages in the presence of P. gingivalis LPS was examined 
at two different doses (1 µg/ml and 1 ng/ml) to measure any effect on TNFα production in 
response to secondary stimulation, the dose of 1 µg/ml  being concurrent with the 
literature104. 
In macrophages differentiated with PMA + 1 µg/ml P. gingivalis, TNFα production was down- 
regulated in response to stimulation with 1 µg/ml P. gingivalis LPS (Figure  4-3 a, p=0.007), 
however, when the macrophages were differentiated in the presence of P. gingivalis LPS at 
1 ng/ml there was slight down- regulation in TNFα, but this was not significant (Figure  4-3 a, 
p=0.179). Then, we went on to examine whether polarisation with P. gingivalis LPS affected 
TNFα production in response to TLR4 ligand, E. coli LPS. In response to challenge by E. coli 
LPS, PMA + P. gingivalis LPS differentiated macrophages down-regulated TNFα production 
(Figure  4-3 d, p<0.001). As seen in response to P. gingivalis  LPS stimulation, 1 µg/ml 
polarising LPS was needed for this down- regulation to be significant (1 ng/ml, Figure  4-3 d, 
p=0.363).  
Next, we examined whether this down- regulation of TNFα production was observed when 
macrophages were polarised in the presence of PMA and E. coli LPS, either in response to 
challenge with TLR2 activating, P. gingivalis  LPS (1ug/ml) or to challenge with the same 
stimulus (1µg/ml E. coli LPS). When macrophages were differentiated with PMA and 1 µg/ml 
or 1 ng/ml E. coli LPS and stimulated with 1 µg/ml P. gingivalis, TNFα production was down -
regulated (p=0.06, p=0.05, Figure  4-3g). Likewise, when macrophages were differentiated 
with PMA and E. coli LPS at both 1 µg/ml or 1 ng/ml, TNFα production was down- regulated 
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in response to 1 µg/ml E. coli LPS (p<0.001, Figure  4-3Error! Reference source not 
found.j).  
Contrary to TNFα, when cells were differentiated in the presence of PMA + P. gingivalis or E. 
coli LPS at 1 µg/ml or 1 ng/ml, there was no difference in IL-1β or IL-6 production in 
response to either E. coli or P. gingivalis LPS: Differentiation with PMA in the presence of 
LPS only affected TNFα production (Figure  4-3b,c,e,f,h,I,k and l). 
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Effects of LPS on cytokine production in M1 polarised macrophages 
After studying the effects of LPS on cytokine production on non-polarised, PMA 
differentiated Mᴓ macrophages, we next examined the effects of LPS during the polarisation 
of macrophages into an M1 phenotype. When cells were polarised in the presence of IFNγ 
and 1 µg/ml P. gingivalis LPS, TNFα production was down-regulated in response to 
secondary challenge with P. gingivalis LPS (p=0.002, Figure  4-4 a), however, when cells 
were polarised with IFNγ and 1 ng/ml P. gingivalis LPS there was no significant change in 
TNFα production (p=0.532, Figure  4-4 a). When cells were polarised with IFNγ + P. 
gingivalis LPS followed by challenge with 1 µg/ml E. coli LPS, TNFα production was down-
regulated (p=0.041, Figure  4-4 d). As reported with P. gingivalis LPS, secondary stimulation 
with E. coli LPS in cells polarised with IFNγ + 1 ng/ml P. gingivalis LPS had no effect on 
TNFα production (p=0.085, Figure  4-4 d).  
When cells were polarised with IFNγ + 1 µg/ml E. coli LPS, TNFα production was down-
regulated in response to secondary stimulation with 1 µg/ml P. gingivalis LPS (p=0.006, 
Figure  4-4 g) but when M1 polarisation occurred in the presence of 1 ng/ml E. coli LPS, 
there was no significant effect on TNFα production (p=0.110,Figure  4-4 g). The same effect 
was witnessed when M1 cells were polarised with IFNγ + E. coli LPS and challenged with 1 
µg/ml E. coli LPS, with 1 µg/ml polarising E. coli LPS down-regulating TNFα production 
(p<0.001, Figure  4-4 j), but 1 ng/ml polarising E. coli LPS was not enough to elicit this 
response (p=0.431, Figure  4-4Error! Reference source not found. j). 
After measuring the effect of LPS polarisation in TNFα production, we went on to measure 
the effects on IL-1β production. When cells were polarised with IFNγ + 1 µg/ml P. gingivalis 
LPS then stimulated with 1 µg/ml P. gingivalis LPS, IL-1β production was down-regulated 
(p=0.026, Figure  4-4Error! Reference source not found. b). Polarisation with 1 ng/ml P. 
gingivalis LPS did not result in IL-1β down-regulation in response to secondary stimulation 
with 1 µg/ml P. gingivalis LPS (p=0.118, Figure  4-4Error! Reference source not found. b). 
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In response to challenge with E. coli LPS, M1 cells polarised in the presence of IFNγ and 1 
µg/ml or 1 ng/ml P. gingivalis LPS down-regulated IL-1β production (p=0.04, p=0.027, 
Figure  4-4 eError! Reference source not found.).  
Next, we examined the effects of E. coli LPS during M1 polarisation on cytokine response to 
P. gingivalis LPS or E. coli LPS. Cells polarised with IFNγ and 1 µg/ml and 1 ng/ml E. coli 
LPS down- regulated IL-1β production in response to P. gingivalis LPS (p=0.002, p=0.0034, 
Figure  4-4 h), whereas in response to secondary stimulation with E. coli LPS, IL-1β was only 
significantly down- regulated when the cells were polarised with 1 µg/ml E. coli LPS 
(p<0.001, Figure  4-4 k). 
As seen in the PMA differentiated Mᴓ macrophages, there was no change in IL-6 production 
in response to P. gingivalis or E. coli LPS when cells were polarised to an M1 phenotype in 
the presence of P. gingivalis or E. coli LPS (Figure  4-4 c, f, i and l).   
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Effects of LPS on cytokine production in M2 polarised macrophages 
Finally, the effects of LPS during M2 polarisation on cytokine production were examined. 
When cells were polarised in the presence of IL-4 + 1 µg/ml P. gingivalis LPS, TNFα 
production was down -regulated in response to challenge with 1 µg/ml  P. gingivalis  LPS 
(p=0.004, Figure  4-5 a), whereas there was no significant effect on TNFα production when 
cells were polarised with 1 ng/ml P. gingivalis  LPS (p=0.431, Figure  4-5 a). Likewise, TNFα 
production was down-regulated in response to challenge with 1 µg/ml E. coli LPS when 
polarised with 1 µg/ml P. gingivalis LPS but not at 1 ng/ml (p<0.001 and p=0.129, Figure  4-5 
d). 
Conversely to polarisation with P. gingivalis LPS, TNFα production was down-regulated in 
M2 macrophages when polarised in the presence of both 1 µg/ml and 1 ng/ml E. coli LPS in 
response to challenge with P. gingivalis LPS (p=0.024 and p=0.038, Figure  4-5 j). 
Furthermore, M2 macrophages down- regulated TNFα production in response to E. coli LPS 
when polarised with E. coli LPS at both 1 µg/ml and 1 ng/ml (p<0.001 and p=0.003, 
Figure  4-5 g). 
The only change in IL-1β  production in M2 macrophages was when cells were polarised in 
the presence of IL-4 + 1 µg/ml P. gingivalis  LPS and challenged with E. coli LPS (p=0.049, 
Figure  4-5 e). Polarisation with P. gingivalis LPS followed by stimulation with P. gingivalis 
LPS had no effect on IL-1β production (p=0.063, Figure  4-5 b).  Likewise, polarisation with E. 
coli LPS had no effect on IL-1β production in response to secondary stimulus with either P. 
gingivalis or E. coli LPS (Figure  4-5 k and h).  
As with the other macrophage phenotypes, IL-6 production was not affected by polarisation 
with LPS (Figure  4-5 c, f, I and l).  
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Table  4-1: summary of cytokine modulation in macrophages polarised with P. 
gingivalis or E. coli LPS 
  
Stimulated with: 
P
o
la
ri
se
d
 w
it
h
: 
  
P. gingivalis  LPS 
(TLR2) 
 
E. coli LPS 
(TLR4) 
 
1 µg/ml 
PgLPS 
 
 TNFα  (PMA, M1 & M2) 
 
          IL-1β (M1) 
  
TNFα  (PMA, M1 & M2) 
 
          IL-1β (M1 & M2) 
 
1 ng/ml 
PgLPS 
 
No effect 
 
  TNFa (PMA) 
IL-1Β (M1) 
 
1 µg/ml E. 
coli LPS 
  
TNFα  (PMA, M1 & M2) 
 
          IL-1β (M1) 
  
TNFα  (PMA, M1 & M2) 
 
          IL-1β  (M1) 
 
1 ng/ml E. 
coli LPS 
         
          TNFα (M2) 
 
          IL-1β  (M1) 
 
          TNFα (PMA & M2) 
 
 
 
Toll-like receptor activation by Porphymonas gingivalis LPS 
 
It is possible that differential cytokine responses to LPS following polarisation with P. 
gingivalis or E. coli LPS are due to differential utilisation of TLR signalling pathways. E. coli 
LPS is an established TLR4 ligand, but the TLR pathway utilised by P. gingivalis LPS is still 
contested. To confirm the role of TLR2 and TLR4 in P. gingivalis LPS signalling in our model,  
blocking antibodies to TLR2 and TLR4 were used in stimulation experiments. 
Briefly, macrophages were incubated with blocking antibodies specific for putative P. 
gingivalis LPS receptor, TLR2, or established LPS receptor, TLR4. After 30 minutes 
incubation, any unbound antibody was removed by washing the cells 3 times in PBS. Cells 
were then stimulated with 1 µg/ml P. gingivalis LPS for 24 hours, and supernatants were 
collected and stored at -20°C until assay for TNFα, IL-1β and IL-6 by ELISA.  
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Figure  4-6: TNFa production is dependent on TLR2 signalling. Data represent 
the mean of three independent experiments, performed in triplicate, +/- standard 
deviation. 
Figure  4-7: IL-1β production is dependent on TLR2 signalling . Data 
represent the mean of three independent experiments, performed in triplicate, 
+/- standard deviation. 
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Incubation with anti-TLR2 antibodies inhibited TNFα production in M1 (p<0.001) 
macrophages in response to P. gingivalis LPS, whereas blocking anti-TLR4 did not. 
(Figure  4-66).  
Incubation with anti-TLR2 antibodies also inhibited IL-1β production, and whilst  (p=0.006, 
Figure  4-77 ) there was evidence for inhibition of IL-1β production by anti-TLR4 antibodies 
this did not reach statistical significance (p=0.072, Figure  4-77). Incubation with anti-TLR2 
and anti-TLR4 antibodies inhibited IL-6 production in M1 macrophages (p=0.001, p=0.001, 
Figure  4-88). 
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Figure  4-8: IL-6 production is dependent on TLR2 and TLR4 signalling . 
Data represent the mean of three independent experiments, performed in 
triplicate, +/- standard deviation. 
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Table  4-2: Summary of toll like receptor utilisation by P. gingivalis LPS in M1 and M2 
polarised macrophages 
Cytokine Cell Receptor 
TNFα M1 TLR2 
IL-1β M1 TLR2 
IL-6 M1 TLR2 and TLR4 
 
Surface expression of TLR2 and TLR4 in un-stimulated and P. gingivalis polarised 
macrophages 
 
Polarising macrophages to an MØ, M1 or M2 phenotype in the presence of P. gingivalis LPS 
reduces their production of TNFα in response to secondary stimulation. IL-1β production was 
down-regulated in M1 only.  Is this because P. gingivalis LPS reduced surface expression of 
LPS receptors TLR2 and TLR4? 
To address this, THP-1 were polarised to PMA, M1 or M2 phenotypes according to the usual 
protocol (described in chapter 3), in the presence or absence of 1 µg/ml P. gingivalis LPS for 
24 hours. TLR2 and TLR4 expression was assayed by flow cytometry.  
In the non-polarised (PMA) macrophages, expression of both TLR2 and TLR4 was down- 
regulated when treated with P. gingivalis LPS during differentiation (Error! Reference 
source not found.10) the M1 polarised cells, TLR2 and TLR4 expression was also 
decreased (Error! Reference source not found.0). The presence of P. gingivalis LPS 
during M2 polarisation however led to an increase in TLR2 and TLR4 expression compared 
to polarisation without LPS (Error! Reference source not found.0Figure  4-8),  though this 
was not statistically significant. 
There was no significant difference in TLR2 or TLR4 expression between PMA, M1 and M2 
macrophages (Figure  4-99).   
× 100 
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Figure  4-60: Percentage change in TLR2 and TLR4 expression in macrophages polarised in the presence 
of P. gingivalis LPS. PMA, M1 and M2 macrophages were incubated with PE conjugated anti -TLR2 and anti -
TLR4 antibodies and expression was analysed by flow cytometry. Data represent the mean of 5 independent 
experiments +/- standard deviation 
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Figure  4-9: TLR2 and TLR4 expression in PMA, M1 and M2 macrophages. PMA, M1 and M2 
macrophages were incubated with PE conjugated anti -TLR2 and anti -TLR4 antibodies and 
expression was analysed by flow cytometry. Data represent the mean of 5 independent experiments 
+/- standard deviation. 
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Discussion 
 
When macrophages were polarised with 1 µg/ml P. gingivalis LPS, all cell types down- 
regulated TNFα production upon secondary stimulus with P. gingivalis LPS or E. coli LPS. 
Polarising with 1 ng/ml P. gingivalis LPS was not enough to elicit this effect in any of the cell 
types. The only cell type to down- regulate IL-1β production following P. gingivalis LPS 
polarisation was M1, but again polarising with 1 ng/ml P. gingivalis LPS was not enough to 
elicit the same effect. Both M1 and M2 down- regulated IL-1β in response to E. coli LPS 
when polarised with 1 µg/ml P. gingivalis LPS, although in the M1, 1 ng/ml was enough to 
replicate this response. There was no effect on IL-6 production in any of the cell types, under 
any of the polarisation conditions.  
When polarised with E. coli LPS, all cell types down -regulated their TNFα response to P. 
gingivalis LPS challenge, and in the M2s, 1 ng/ml was enough to elicit the same response. 
As with P. gingivalis LPS polarising, the only cell type to down- regulate IL-1β in response to 
secondary P. gingivalis LPS challenge was M1, and this was only when polarised with 1 
µg/ml  P. gingivalis LPS. All cell types down- regulated TNFα production in repose to E. coli 
LPS challenge, and in MØ and M2 cells, polarising with 1 ng/ml E. coli LPS was enough to 
elicit the same response, the M1 cells however needed the higher dose (1 µg/ml) for this 
down- regulation to happen.  Only M1 down- regulated IL-1β production in response to E. 
coli LPS challenge. As seen with P. gingivalis LPS polarisation, there was no effect on IL-6 
production in any of the cell types.  
In summary, there was a down-regulation of M1 associated cytokines TNFα and IL-1β in 
response to a secondary LPS stimulus in macrophages polarised in the presence of LPS 
(summarised in Table  4-1). The down-regulation of cytokine production may be due to 
expression of negative regulators of TLR signalling. It has previously been demonstrated 
that P. gingivalis LPS induces regulatory factors in macrophages,  leading to the formation of 
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regulatory NFκB p50 homodimers 244 and up-regulation of IRAK-M expression in THP-1 
macrophages245. However, SOCS3 and 6 are reported to be up-regulated in response to P. 
gingivalis LPS in gingival epithelial cells246. The effects of P. gingivalis LPS on expression of 
other negative regulators of TLR signalling, such as PPARγ, TOLLIP, SHIP are yet to be 
investigated. Given that IRAK- M and NFκB  homodimers are preferentially induced by P. 
gingivalis LPS compared with E. coli LPS, and that the same levels of cytokine down- 
regulation are observed in both LPS species, it is not likely that up-regulation of negative 
regulators are the cause of cytokine down-regulation. 
Differential transcriptional regulation of TNFα and IL-6/IL-1β production in response to TLR 
ligation may have some part to play in the differing levels of down-regulation seen in the 
present results. Nuclear proteins C/EBPδ, IκBζ, IκB-NS, AFT3 and Zc3h12a regulate IL-6 
expression, whereas TNFα  expression is regulated by TTP 226. It may be that these proteins 
are differentially regulated in endotoxin tolerance, although this remains to be investigated.  
 
Alternatively, this down- regulation of cytokine production may be due to skewing of the 
macrophages towards an M2 –like phenotype. Previous studies have reported that P. 
gingivalis up- regulates the M2 markers IRAK-M and IL-1Ra247,248 and that periodontal 
infection with P. gingivalis leads to the development of a population of myeloid derived 
suppressor cells (MDSCs) that have similar characteristics to M2 macrophages249. This does 
not account for the down-regulation of cytokines in response to E. coli, however. The 
expression of M2 characteristic cytokines in the present study remains to be investigated, 
although a previous study has shown that IL-10 production is not up- regulated upon 
repeated exposure to LPS250.  
It has been argued that M2 polarisation is in fact a manifestation of endotoxin tolerance250. A 
comprehensive study of gene expression on Pseudomonas aeruginosa LPS tolerised human 
macrophages by Pena et al (2001) revealed that tolerised macrophages exhibit similar gene 
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expression profiles as IL-10 polarised M2 macrophages, with an up- regulation of M2-
associated chemokines CCL-22, CCL-24, scavenger receptors MARCO and CD23, CD163 
growth factors VEGF and FGF-2, matrix metalloproteinase 7 and 9, wound healing factor 
versican and formyl peptide receptor ligand 1 (activation of formyl peptide receptor inhibits 
expression of M1 cytokine IL-12p70251). They demonstrated a concomitant down- regulation 
of M1 associated inflammatory mediators TNFα, COX2 and tissue factor (TF), and 
chemokines CCL-3 and CCL-20250. Moreover, P. gingivalis  LPS induces expression of 
tolerogenic molecules ILT-3 and B7-H1 on dendritic cells and human PBMCs, which is 
further increased upon a secondary stimulation with P. gingivalis LPS, suggesting the P. 
gingivalis plays a tolerogenic role252.  
A study by Zaric et al (2011) reports that TNFα production is down- regulated in response to 
P. gingivalis and E. coli LPS tolerising, whilst IL-8 is unaffected in THP-1 cells. 
Physiologically, this leads to the same level of neutrophil recruitment but lower levels of 
neutrophil apoptosis induced by TNFα in P. gingivalis LPS tolerised cells253. The present 
study did not address IL-8, however a similar pattern was found in IL-6 production, which 
remained at the same levels as cells polarised without exposure to LPS, although this was 
the case for both E. coli and P. gingivalis LPS. 
An earlier study by Martin et al (2001) reported that endotoxin tolerance induced by E. coli 
LPS in THP-1 led to down- regulation of TNFα, IL-1β and IL-6, whereas endotoxin tolerance 
induced by P. gingivalis  LPS resulted in down-regulation of IL-1β production only 234. These 
findings differ from the present study in that TNFα production was down-regulated by prior 
exposure to P. gingivalis LPS, but there was no change in IL-6 levels from naïve (LPS free) 
cells stimulated with LPS. However, both studies are in agreement that IL-1β was down-
regulated by prior exposure to either LPS species. In contrast to the Martin et al (2001) study, 
and in common with results from the present study, Muthukuru et al (2005) reported that 
TNFα and IL-1β  were down- regulated in response to repeated exposure of PBMCs to P. 
gingivalis LPS, but IL-6, IL-8 and IL-10 were down- regulated to a much lesser extent62. The 
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discrepancy in results may be born from the fact that the Martin et al (2001) study used  
THP-1 cells differentiated for 72 hours in 10 ng/ml PMA, washed 3 times and rested 
overnight, compared to the various polarising treatments used in the present study, i.e. 
macrophage polarisation may affect tolerogenic mechanisms induced by E. coli and P. 
gingivalis LPS.  
Dobrovolskaia et al (2003) reported that both E. coli LPS and synthetic TLR2 ligand   
PAM3CSK4 induced homotolerence but not heterotolerance in murine macrophages. 
PAM3CSK4 pre-treatment up-regulated TNFα production in response to E. coli LPS. 
Porphyromonas gingivalis LPS also induced homotolerance, but like PAM3CSK, E. coli pre-
treatment up-regulated TNFα production in response to secondary stimulus with P. gingivalis 
LPS. In contrast, results from the present study showed that E. coli LPS pre-treatment led to 
a down-regulation of TNFα production when subject to a secondary stimulation by P. 
gingivalis LPS. However, the studies are in agreement in that P. gingivalis pre-treatment led 
to a down-regulation of TNFα production when subject to a secondary stimulation by E. coli 
LPS254. 
 
The present study showed little difference in the down- regulation of cytokines in response to 
polarisation in the presence of either LPS species. Previous studies have shown that P. 
gingivalis LPS is a weaker inducer of endotoxin tolerance than E. coli LPS, and that this is 
down to differential use of TLRs and intracellular signalling pathways, with E. coli LPS 
reducing degradation of NFκB inhibitors IκKα and IκKβ and TLR4 surface expression upon 
secondary stimulation, whereas P. gingivalis LPS up-regulates TLR2 and CD14 expression 
and degrades inhibitory IκKβ, thereby rendering cells less responsive to tolerance 234. It may 
be that the different macrophage differentiation protocols between the two studies affect the 
response to secondary stimulation to LPS pre –treated cells.  
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LPS pre-treatment activates the MyD88 independent pathway (via TLR4 signalling) leading 
to production of IFNβ100, and IFNβ production leads to E. coli induced endotoxin tolerance in 
THP-1 cells232,253. A previous study by Zaric et al (2011) reported that P. gingivalis signalling 
via TLR2 did not induce IFNβ production, thereby rendering the cells only partially tolerised 
(reduced TNFα production but IL-8 levels remained the same)253. Only TLR4, and not TLR2, 
can active the TRIF pathway, therefore inducing IFNβ mediated tolerance. However, there is 
still a down-regulation in cytokine production induced by P. gingivalis LPS, a purported TLR2 
ligand. Therefore, either P. gingivalis LPS is signalling through TLR4, or another mechanism 
induces tolerance via TLR2 signalling. In order to ascertain P. gingivalis LPS receptor 
utilisation in our model, MØ, M1 and M2 macrophages were pre-incubated with neutralising 
anti- TLR2 or TLR4 antibodies prior to stimulation with P. gingivalis or E. coli LPS.  
 
Anti -TLR4 antibodies inhibited IL-6 production in M1 (p=0.001). IL-1β was also inhibited in 
M1, but this did not reach statistical significance. A study by Darveau et al (2004) showed 
that P. gingivalis LPS has the ability to signal through both TLR2 and TLR4213. Data from the 
present study also demonstrate that P. gingivalis can utilise both TLRs under certain 
conditions; M1 production of IL-6 is dependent on TLR2 and TLR4.  
Following confirmation of TLR utilisation by P. gingivalis LPS, we sought to determine levels 
of TLR2 and TLR4 surface expression on M1 and M2 polarised macrophages, as this is yet 
to be described. M1 may express higher levels of TLR2 and 4 than MØ and M2 
macrophages, but there was no statistically significant difference. This data could in part 
explain why M1 produce higher levels of inflammatory cytokines than M2. However, caution 
must be taken when interpreting these results. Expression levels of TLR2 and TLR4 were 
normalised to fluorescence produced by cells alone (auto-fluorescence) because the isotype 
control antibody was binding specifically to an unknown ligand on the M1 polarised 
macrophages. As this isotype control binding was only present in the M1 macrophages, and 
changed markedly between M1 and MØ/M2 macrophages, it was unsuitable to use as a 
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normalisation point255. Therefore, further experiments to address expression levels of TLR2 
and TLR4 are needed to confirm these findings.  
After measuring the levels of TLR2 and TLR4 expression on the surface of MØ, M1 and M2 
macrophages, we next sought to determine whether expression levels were modulated in 
response to polarisation in the presence of P. gingivalis LPS.  As shown in Error! Reference 
source not found.10, the presence of P. gingivalis LPS during polarisation down-regulated 
TLR2 and TLR4 expression in MØ and M1 macrophages, but up-regulated TLR2 and 4 
expression in M2 macrophages. Up-regulation of TLR2 on THP-1 cells in response to a 
single stimulation by P. gingivalis LPS has been demonstrated in previous studies62,252,256, 
but down- regulation of TLR2 and TLR4 upon the second stimulation has also been noted 62. 
Contrary to MØ and M1 macrophages, there is an up- regulation of TLR2 and TLR4 surface 
expression in response to P. gingivalis LPS polarisation in M2 macrophages, with a 
concomitant down-regulation of cytokine production. This further suggests that there is a 
different mechanism involved in this down-regulation of cytokines in response to repeated 
LPS exposure in M1 and M2 macrophages. The expression of anti-inflammatory cytokines 
remains to be investigated. It is possible that P. gingivalis LPS might up- regulate TLRs in 
M2 macrophages in order to increase production of anti –inflammatory cytokines to aid 
resolution of inflammation. Indeed, data from the previous chapter shows that P. gingivalis 
up- regulates IL-10 and TGF-β in M2 to a greater extent than M1. This provides an exciting 
avenue of investigation for future research. 
When taken together with the down- regulation of cytokine production in response to 
polarisation with P. gingivalis LPS,this suggests that the down- regulation of cytokines is due 
to of a down- regulation of TLRs. However, previous studies have reported that endotoxin 
tolerance is not likely to be solely due to a down-regulation of TLR4/MD2 at the cell surface, 
as this is transient257, and cells over expressing TLR4/MD2 are still readily tolerised258.  
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Data from the present study demonstrates that M2 macrophages are sensitive to TNFα 
down-regulation at ng/ml concentrations of LPS, whereas M1 require µg/ml concentrations 
to elicit the same effect. This suggests that M2 macrophages may be more readily tolerised 
than M1, at least with respect to TNFα production, which given their anti-inflammatory role 
may prove a viable hypothesis. It has been previously reported that type 1 interferon priming 
before LPS (TLR4) stimulation in M2 macrophages leads to an increase in the use of the 
MyD88 independent (TRIF) pathway and autocrine production of IFNβ compared with M1. 
This preferential induction of IFNβ in M2 macrophages accounted for their signature low 
inflammatory cytokine production, and the lack of IFNβ in M1 led to an up- regulation of M1 
cytokines259. This provides a possible mechanism whereby M2 are more readily tolerised 
than M1.  
This study demonstrates for the first time that M2 macrophages down- regulate cytokine 
production in response to repeated exposure to P. gingivalis and E. coli LPS, and that the 
cytokines down-regulated are different from M1.  Thus, future studies should be designed to 
investigate the mechanisms of tolerance induction in M2 versus M1 macrophages.  
To date, no studies have described the levels of TLR2 and TLR4 expression on M1 versus 
M2 macrophages. The present study tentatively suggests that M1 macrophages express 
higher levels of TLR2 and TLR4 than M2 macrophages, and further investigation is needed 
in order to confirm this finding.   
The present data suggests for the first time that TLR signalling by P. gingivalis LPS may 
differ between M1 and M2 macrophages. Both anti-TLR2 and anti- TLR4 inhibited IL-6 
production in M1 macrophages, but were unable to inhibit IL-6 production in M2, suggesting 
a possible difference in regulation of IL-6 production. Furthermore, IL-1β production was 
dependant on TLR2 signalling alone in M1 macrophages, whereas ligation of either TLR2 or 
TLR4 induced IL-1β in M2 macrophages. Taken together, the data presented in this study 
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suggest that TLR signalling pathways that lead to the production of inflammatory cytokines 
may be differentially regulated in M1 and M2 macrophages.  
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Chapter 5 - Influence of oral squamous cell carcinoma culture 
supernatants on macrophage responses to Porphyromonas 
gingivalis 
 
Introduction 
 
As of 2010, oral cancer is the 6th most common cancer across the globe, of which over 90% 
are squamous cell carcinoma  (OSCC) 123. OSCC is a multifactorial disease and  has been 
linked to oral leukoplakia 125, HPV infection126,260, periodontal disease 127,261, oral bacterial 
species 128, alcohol and tobacco use 129,130. Despite intensive research into all aspects of 
OSCC, from epidemiology, through treatment and prevention, to the cellular and molecular 
basis of the disease, the global incidence and mortality of OSCC is increasing262. Thus, 
investigations into the mechanisms that drive oral cancer are required to provide novel 
therapeutic targets. To this end, the cell line H357 , established by Prime et al (Sheffield, 
UK), has been used  to investigate pathological mechanisms in OSCC 263–265.  To date, H357 
have been shown to produce MMP -2 and -9 265 αvβ1 integrin 266, ICAM-1267, super oxide268 
and TGF-β 269, however the pro-inflammatory cytokine producing capability of these cells 
has not been investigated. Furthermore, the production of inflammatory cytokines by oral 
epithelial cells in general is not well established, particularly in response to the oral 
bacterium P. gingivalis. Several studies have shown that IL-1β , IL-6, IL-8, GM-CSF and 
TNFα are up-regulated in primary gingival epithelial cells and an oral epithelial cell line  in 
response to viable and non-viable  P. gingivalis270–272. Conversely, other studies have 
reported that P. gingivalis inhibits IL-8 and ICAM-1 in primary gingivalis epithelial cells273,274.  
It has long been established that infection with particular bacteria or viruses can lead to the 
malignant transformation of epithelial cells; the enterobacterium Helicobacter pylori, for 
example,  is a recognised gastric carcinogen118. Evidence is accumulating that the 
periodontal pathogen P. gingivalis has a role in the development of OSCC119–121, however, 
other groups have shown that P. gingivalis colonises control tissue rather than tumour 
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 tissue 275. 
 Since OSCC cells and P. gingivalis may come into contact in vivo, the first part of this study 
was designed to assess the cytokine response of H357 to a major virulence factor of P. 
gingivalis: LPS. 
Recently, OSCC research has focused on the interaction between tumour cells and non- 
tumour cells in their microenvironment, such as fibroblasts and infiltrating immune 
cells146,276,277. Of the infiltrating immune cells, macrophages have been shown to play a 
pivotal role in promoting a pro-tumoural environment. Monocytes recruited to tumours by 
MCP-1278, produced by the cancer cells, differentiate and polarise into functional effector 
macrophages depending on factors they encounter in their microenvironment279. In OSCC, 
MCP-1 is significantly elevated in cancerous lesions compared to healthy mucosa 132. The 
accumulation of macrophages around the tumour site is associated with poor prognosis 146, 
which is even poorer if the macrophages develop into a suppressive,  M2 phenotype222. 
M2 macrophages facilitate tumour growth and survival by immune suppression (via 
production of anti-inflammatory cytokines such as IL-10 and TGF-β), production of 
angiogenic factors (VEGF), and MMPs and cytokines to aid metastasis (reviewed in280). 
Recently, pro-inflammatory cytokines have also been shown to play a detrimental role in 
cancer. In response to pathogenic stimuli, macrophages produce inflammatory mediators 
such as reactive oxygen and nitrogen species, and cytokines (such as TNFα, IL-1β, IL-6 and 
IL-8) leading to oxidative and nitrative DNA damage138, enhanced cell growth and 
proliferation, inhibition of apoptosis and production of angiogenic factors (reviewed in135).  
TNFα and IL-6 are associated with poor prognosis in several carcinomas139–141, and 
inhibitors of both are in clinical trials for the treatment of cancer142,143.   
In the tumour environment, macrophages exhibit  extraordinary plasticity, adapting their 
phenotype and effector functions in response to local stimuli148. In general, tumour 
associated macrophages (TAMs) acquire an M2 like phenotype148, but in colorectal cancer 
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and non-small cell lung carcinoma, the infiltrating macrophages display a more pro-
inflammatory, M1 like phenotype149,150, and some even develop into a mixed M1/M2 
phenotype 151.  Macrophage polarisation however is not terminal; it has been demonstrated 
both in vivo and in vitro that macrophage polarisation can be reversed by exposure to 
opposing polarising factors152,153. This plasticity can be exploited to develop anti-cancer 
therapies.152 One such mechanism proposed to overcome the immunosuppressive 
characteristics of TAMs and drive them to a more anti-tumoural activation state, is bacterial 
LPS. Indeed, LPS or analogues thereof, have been used  in human clinical trials as an anti-
cancer therapy155–158.  The effects of LPS on H357 cells is yet to be described. 
OSCC and normal epithelial cells produce factors into the local microenvironment that affect 
macrophage behaviour and drive them to a particular activation state, which my be pro- or 
anti- tumoural. It is therefore necessary to investigate the effects of LPS on OSCC produced 
factors as they may influence macrophage behaviour in the microenvironment.  
Evidently, TAM behaviour is far from clear; both pro- and anti –inflammatory mediators play 
a role in cancer, and macrophages spanning the spectrum of phenotypes have been 
described surrounding tumours. Thus, TAM polarisation is likely to be dictated by the tumour 
location and stage of progression. Because of this, it is vital that TAM behaviour is studied in 
the context of specific diseases, rather than making inferences from other cancer types. 
Given the limited data on TAM behaviour in OSCC, and the lack of characterisation of 
cytokine responses in H357 cell, the present study had the following aims: 
i. To determine the cytokine response of H357 cells to P. gingivalis LPS. 
ii. To determine the effect of OSCC produced soluble factors on macrophage 
polarisation and subsequent responses to P. gingivalis LPS.   
109 
 
Results 
H357 cytokine responses to P. gingivalis LPS 
 
In this study, the response of H357 cells to P. gingivalis LPS was characterised in a time- or 
dose-dependent manner. Firstly, cytokine expression was measured in response to 
increasing doses of P. gingivalis LPS, at 0, 10, 100 and 1000µg/ml for 24 hours. H357 cells 
did not produce TNFα or IL-1β, either constitutively or in response to P. gingivalis LPS, but 
did produce high levels of IL-6 (Figure  5-1). Next, to see if time was a factor in cytokine 
production, H357 cells were incubated with 1 µg/ml  P. gingivalis LPS for 6, 24 and 48 hours. 
Supernatants were harvested after stimulation and assayed for TNFα, IL-1β and IL-6 by 
ELISA.  There was no difference in response over the time course (6, 24 or 48 hours) for 
TNFα or IL-1β or IL-6 (Figure  5-2)  
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Figure  5-1: H357 dose response to P. gingivalis LPS. H357 cells were seeded at 5x103 cells/cm2 and grown to 
confluence. Culture media was removed and replaced with fresh media alone, or containing increasing doses of 
P. gingivalis LPS. After 24 hours incubation, supernantants were collected and stored at -20°C until assayed for 
cytokines by ELISA. Data represents mean ± standard deviation from two independent experiments performed in 
triplicate wells. 
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As neither time nor concentration of P. gingivalis affected cytokine release from H357 cells, 
the cells were tested for surface expression of the LPS receptors TLR2 and TLR4 by flow 
cytometry. Briefly, H357 cells were grown to confluence in 6 well plates and harvested using 
an enzymatic detachment solution (see methods and materials). Cells were washed in PBS 
and counted, and non-specific binding was blocked using 1% PBS/BSA for 30 minutes, on 
ice. Next, cells were washed and incubated with PE- conjugated anti TLR2 or TLR4 
antibodies or an isotype matched control for a further 30 minutes in the dark, on ice (see 
methods and materials chapter 2: Flow cytometry p42).  
Surface expression of Toll-like receptors 2 and 4 on H357 cells 
 
 
 
 
 
 
 
 
Figure  5-3:  TLR2 and TLR4 surface expression on H357 cells. H357 cells were grown to confluence, 
harvested and assayed for TLR2 (a) and 4 (b) expression by flow cytometry. Histograms are representative of 
n=2 independent experiments. Mean fluorescence intensity (c) was normalised to isotype control and is 
representative of two independent experiments ± standard deviation. Student’s T-test was used to test for 
differences in MFI. 
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Both TLR2 and TLR4 were detected at low levels on the surface of H357 cells (Figure  5-3 a 
and b), suggesting whilst that they possess the receptor machinery needed to respond to 
LPS, the low levels may mean that any slight up-regulation in cytokine production induced by 
ligation of these receptors may go undetected.. Compared with macrophages, levels of TLR 
expression a very low (see Figure  4-9).  There is not a significant difference between levels 
of TLR2 and TLR4 expression (Figure  5-3 cFigure  5-5, p=0.33). It has previously been 
reported that co culture with macrophages modulates the behaviour of cancer cells by 
increasing invasiveness via TNFα140. To see if  co culture with macrophages could affect 
other properties of cancer cells, such as cytokine production , H357 cells were co cultured 
with PMA, M1 or M2 macrophages for 24 hours during exposure to P. gingivalis LPS in a 
trans-well co culture system (see methods and materials chapter 2:  H357 and THP-1 co-
culture experiments p38). 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-4: IL-6 expression by macrophage co-cultured H357 cells. H357 cells were grown to confluence on 
trans-well inserts and exposed to 1 µg/ml P. gingivalis LPS in co culture for 24 hours. Supernatants were 
harvested and stored at -20°C until assay for cytokines by ELISA. Tests for statistically significant differences 
were performed using one way ANOVA.  
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Although perhaps a very slight increase in IL-6 production in response to P. gingivalis  LPS, 
the only conditions where IL-6 increased significantly from control (no LPS) was during co 
culture with M1 (P=0.03), however, levels of IL-6 did not reach those of H357 cultured alone 
and challenged with LPS (P=0.533).  
Effects of H357 conditioned media on the macrophage cytokine responses to P. 
gingivalis LPS 
 
To measure the effects of factors produced by the OSCC cell line on the macrophage 
polarisation and subsequent response to P. gingivalis LPS, conditioned media from H357 
cells was added to macrophage cultures during the polarisation process. Briefly, to generate 
conditioned media, H357 cells were grown to confluence in 25cm2 flasks. At confluence, 
culture media was removed and replaced with fresh media. Cells were incubated for 24 
hours and harvested into centrifuge tubes, where they were spun down to remove any 
cellular debris. The cell free supernatants were collected and stored at -20°C until needed 
for experiments. Conditioned media was then used in experiments to investigate whether 
factors produced by the H357 cells affected the response of macrophages to P. gingivalis 
LPS and the polarisation process. Macrophages were polarised in the presence or absence 
of H357 conditioned media and stimulated with 1 µg/ml P. gingivalis LPS for 24 hours. 
Cytokine production was measured by ELISA.  
Compared to macrophages polarised in normal culture media (control), IL-1β (Figure  5-6) 
and IL-6 (Figure  5-7) production in response to P. gingivalis LPS was amplified in 
macrophages polarised in the presence of H357 conditioned media. This was observed in all 
polarisation conditions (PMA, M1 and M2: p<0.05). TNFα production, however, was not 
affected (Figure  5-5). 
The addition of conditioned media alone was enough to up regulate IL-6 production from all 
macrophage phenotypes (p=0.001), however, this was around 10 fold lower than seen with 
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the addition of P. gingivalis LPS (Figure  5-8). The presence of H357 conditioned media 
alone did not effect TNFα or IL-1β production. 
PMA, M1 and M2 macrophages retained their respective cytokine profiles, with M1 being the 
highest producers of TNFα, IL-1β  and IL-6, therefore it is not likely that the conditioned 
media affected phenotypic polarisation per se, but the same amplification of cytokines 
production was seen across all phenotypes. 
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Figure  5-5: TNFα production in MØ, M1 and M2 macrophages polarised in the presence or 
absence of H357 conditioned media. Macrophages were polarised according to the usual protocol, 
in the presence or absence of H357 conditioned media for 24 hours. Cells were then stimulated with 
P. gingivalis LPS for a further 24 hours. TNFα production was measured by ELISA. Data represent 
mean of n=3 independent experiments ± standard deviation. Tests for significant differences between 
control media and conditioned media were conducted using Student’s T test. 
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Figure  5-6: IL-1β production in MØ, M1 and M2 macrophages polarised in the presence 
or absence of H357 conditioned media. Macrophages were polarised according to the usual 
protocol, in the presence or absence of H357 conditioned media for 24 hours. Cells were then 
stimulated with P. gingivalis LPS for a further 24 hours.IL-1β production was measured by 
ELISA. Data represent mean of n=3 independent experiments ± standard deviation. Tests for 
significant differences between control media and conditioned media were conducted using 
Student’s T test.  
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Figure  5-7: IL-6  production in MØ, M1 and M2 macrophages polarised in the presence or absence of 
H357 conditioned media: IL-6  production in MØ, M1 and M2 macrophages polarised in the presence or 
absence of H357 conditioned media. Macrophages were polarised according to the usual protocol, in the 
presence or absence of H357 conditioned media for 24 hours. Cells were then stimulated with P. gingivalis LPS 
for a further 24 hours. IL-6 production was measured by ELISA. Data represent mean of n=3 independent 
experiments ± standard deviation. Tests for significant differences between control media and conditioned 
media were conducted using Student’s T test. 
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Figure  5-8: IL-6 production induced by conditioned media alone. Macrophages were polarised 
according to the usual protocol, in the presence or absence of H357 conditioned media for 24 hours 
then incubated with control media alone for a further 24 hours. Supernatants were harvested and 
assayed for IL-6 by ELISA. Data represent mean of n=3 independent experiments ± standard deviation. 
Tests for significant differences between control media and conditioned media were conducted using 
Student’s T test 
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To see if the amplification of cytokine production in response to P. gingivalis  LPS was dose 
dependant, THP-1 cells were polarised to their respective phenotypes in the presence of  
decreasing dilutions of conditioned media. Neat or diluted H357 conditioned media  (1/5, 
1/25 and 1/125) was added to the THP-1 cells during polarisation. Macrophages polarised in 
normal growth media (in the absence of conditioned media) served as controls. After 
completion of the polarisation process (24 hours), polarising media was removed, the cells 
were washed 3 times in PBS and replaced with fresh media (normal growth media) with or 
without 1 µg/ml P. gingivalis LPS and incubated for 24 hours. Cell free supernatants were 
harvested and assayed for IL-6 by ELISA.  
Levels of IL-6 increased in line with increasing concentrations of conditioned media 
(Figure  5-9). This was universal across all macrophage cell types. As seen in the previous 
experiment (Figure  5-8), conditioned media alone was enough to induce IL-6 production 
from the macrophages without the need for stimulation by LPS.
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Epithelial cells have been shown to respond differentially to different bacterial species281–284. 
To assess whether the amplification of cytokine production was an effect specific to P. 
gingivalis, the experiment was repeated, this time including enterobacterium E. coli LPS as a 
comparison. As previously found under normal polarisation conditions, stimulation of 
macrophages with E. coli LPS resulted in higher cytokine production than stimulation with P. 
gingivalis LPS. This pattern was repeated in macrophages polarised in H357 conditioned 
media. As seen with the P. gingivalis LPS, IL-6 and IL-1β were both up-regulated beyond 
that of levels produced by normally polarised macrophages when they were polarised in the 
presence of H357 conditioned media (Figure  5-10). There was no amplification of TNFα 
production (data not shown). The amplification of cytokine production was not due to LPS in 
the conditioned media, as determined by LAL assay (data not shown).  
At the end of the experiment, a Trypan blue exclusion assay was carried out to confirm cell 
viability following treatment with conditioned media / LPS. Briefly, following removal of 
supernatant, cells were washed three times in PBS and incubated with Accutase to detach 
them from the wells. Triplicate wells were pooled and counted by Trypan blue exclusion 
using a haemocytometer. Viability consistently remained over 97% throughout all the 
treatments (Table  5-1). Interestingly, incubation with conditioned media resulted in an 
increase in cell number compared to incubation with R10 (Figure  5-11) Moreover, the 
increase in cell number was higher in the M2 macrophages than the M1 macrophages. The 
addition of LPS resulted in a less marked increase in cell number, although it was still above 
that of R10 polarised cells, with E. coli LPS reducing less than P. gingivalis LPS.  
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Table  5-1: Viability count of cells polarised in the pressence or abssence of H357 
conditoned media by Trypan blue exclusion 
 
  
  
Cell type Polarised with: Stimulus % Viability 
M1 R10 Ctrl 98.46154 
M1 R10 PgLPS 97.05882 
M1 R10 EcLPS 100 
M2 R10 Ctrl 100 
M2 R10 PgLPS 98.85057 
M2 R10 EcLPS 100 
M1 CM Ctrl 98.34711 
M1 CM PgLPS 100 
M1 CM EcLPS 97.05882 
M2 CM Ctrl 100 
M2 CM PgLPS 99.57082 
M2 CM EcLPS 100 
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Figure  5-11: Difference in cell number following culture with H357 conditioned media. THP-1 cells 
were polarised to M1 or M2 phenotypes in the presence or absence of H357 conditioned media for 24 
hours. Cells were removed from triplicate wells, pooled, and counted using Trypan blue exclusion. Data are 
representative of n=1 experiments. 
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Effects of primary OSCC conditioned media on the macrophage cytokine responses 
to P. gingivalis LPS 
 
It has been argued that cell lines do not accurately replicate the behaviour of primary cells285. 
To confirm whether the amplification of cytokine production seen by H357 cell line 
conditioned media also occurs in response to primary tissues, the experiments were 
repeated using conditioned media from excised human OSCC tumours.  
Freshly isolated OSCC specimens (soft palate/tonsil, posterior maxilla and floor of mouth) 
were washed 3 times in growth media and cultured in 1ml growth media for 48 hours. 
Supernatants were harvested and cell debris was removed by centrifugation. Condition 
media from culture supernatants was added to macrophages during the polarisation phase, 
as per previous experiments. After 24 hours incubation, conditioned media was removed, 
cells were washed 3 times with PBS and fresh media was added to the cells with or without 
P. gingivalis LPS. Supernatants were harvested after 24 hours and assayed for TNFα by 
ELISA.  
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Figure  5-12: TNFα production by MØ, M1 and M2 macrophages polarised in the 
presence of primary OSCC sample conditioned media. Macrophages were 
polarised in the presence or absence of a series of dilutions of OSCC conditioned 
media for 24 hours, then challenged with P. gingivalis LPS for a further 24 hours. Data 
represent the mean of n=3 independent experiments ± standard deviation. 
M1 
M2 
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In response to stimulation by P. gingivalis LPS, MØ and M2 macrophages polarised in the 
presence of OSCC conditioned media exhibited amplified TNFα production compared with 
macrophages polarised in normal growth media. However, this did not reach statistical 
significance. There was no change in TNFα production in the M1 macrophages polarised 
with OSCC conditioned media in response to P. gingivalis  LPS compared with M1 
macrophages polarised in normal growth medium (Figure  5-12).  
Amplification of cytokine production in response to P. gingivalis LPS by macrophages 
polarised in the presence of conditioned media, and potentially primary OSSC specimens, 
would suggest that OSCC cells (primary or cell line) produce factors that affect macrophage 
cytokine production. Thus, primary OSSC sample supernatants were assayed for an array of 
cytokines by ELISA. Excised gingival epithelium was used as a non-cancerous control tissue. 
Freshly isolated tumour and control tissues were washed 3 times in media and cultured for 
48 hours in 1ml fresh media. Supernatants were harvested and cellular debris was removed 
by centrifugation, and then stored at -80°C until assay for IL-10, TGF-β, TNFα, IL-15, IL-6 
and IL-8 by ELISA. 
Control tissues produced higher levels of all cytokines than the OSCC tissues, except IL-5, 
which was produced in higher quantities in the tumour tissue (p= 0.017). Neither control 
tissue nor tumour tissue produced any TNFα, but did produce IL-6, reflecting the behaviour 
of the H357 cells. 
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Figure  5-13: Consitutive production of cytokines in primary OSCC samples versus control tissue 
(gingiva). Samples of OSCC or gingiva were dissociated and cultured for 48 hours. Cytokine production 
was measured by ELISA. Data represent mean ± standard deviation from n=6 samples (6 OSCC vs 6 
control samples). 
128 
 
Discussion 
 
P. gingivalis has been associated with OSCC: it is present in higher numbers on transformed 
mucosa than healthy mucosa, it has been isolated from OSCC tumour cores and it invades 
squamous carcinoma cells 33% more than healthy tissues 1,119,219.  The cell line H357 has 
been used  to investigate pathological mechanisms in OSCC 263–265, but the response of 
these cells to P. gingivalis has not been investigated.  Since OSCC cells and P. gingivalis 
are likely to come into contact in vivo, the first part of this study was designed to assess the 
cytokine response of H357 to a major virulence factor of P. gingivalis: LPS.  
Following 24 hours stimulation with P. gingivalis LPS, there was no TNFα or IL-1β 
production in the H357 cells, either constitutively or in response to LPS. Previous studies 
using SCC cell lines have described a similar lack of TNFα or  IL-1β  production286. The 
same pattern has been reported using healthy excised gingival multilayers cultured in vitro 
215. In fact, Huang et al showed that IL-8 and ICAM-1 expression was down-regulated in 
response to P. gingivalis  274. On the other hand, studies have shown that primary gingival 
epithelial cells do produce IL-8, MCP-1, TNFα and IL-1β in response to  P. gingivalis LPS 
271,287.  
Here, in contrast to TNFα and IL-1β, IL-6 was produced constitutively (between 1836-4430 
pg/ml), in line with  previous studies on squamous cell carcinoma cell lines288. Whilst 
potentially indicating a dose-response, this is not enough to conclude that the H357 cells are 
responsive to P. gingivalis LPS and requires further investigation. Furthermore, the 2006 
Hagemann et al study showed no IL-6 production in response to P. gingivalis in another 
SCC cell line 286. 
It remains to be confirmed whether oral epithelial cells produce cytokines in response to 
bacterial challenge. There have been many different experimental set ups; primary epithelial 
cells or cell lines, viable or non-viable P. gingivalis, yet no consensus has been reached 
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regard cytokine responses to P. gingivalis  in epithelial cells. Data from the present study 
shows that H357 cells, at least, do not respond to P. gingivalis LPS.  
In order for LPS to initiate pro inflammatory cytokine production, it has to bind to its receptor 
on the surface of the cell, in a complex with CD14, LBP and MD211. To see if the un-
responsiveness to LPS seen in the present study was due to a lack of LPS receptors on the 
H357 cells, TLR2 and TLR4 expression was measured by flow cytometry. H357 cells were 
both TLR2 and TLR4 positive. There was no significant difference in expression between the 
TLRs. Concurrent with these results, human gingival epithelial cells have been shown to 
express TLR2 and 4 289–291. The presence of LPS receptors TLR2 and TLR4 on the surface 
of H357 cells with a concurrent unresponsiveness to P. gingivalis LPS throws up a number 
of suggestions: 
• Expression levels of TLR2 and TLR4 are low compared with macrophages 
(Figure  4-9). It may be that the levels of TLRs present on the surface of the H357 are 
not high enough to induce a cytokine response to LPS. 
• Epithelial cells have been shown not express LPS co-receptor, CD14 18,289. It may be 
that the cells are not responding to LPS because of lack of co-receptors.  
• P. gingivalis up –regulates negative regulator of cytokine expression IRAK-M in 
epithelial cells 292. There may be down-stream inhibition of cytokine production in 
response to P. gingivalis LPS TLR ligation. 
• It has been reported that gingival epithelial cells up regulate TNFα, IL-1β  and other 
cytokines in response to whole dead, P. gingivalis  271 284. It may be that epithelial 
cells respond to other virulence factors of P. gingivalis  beside LPS. 
• Uehara et al (2002) demonstrated that for epithelial cells to become responsive to 
LPS, they first had to be primed by IFNγ 15. It may be that epithelial cells need to 
interact with immune cells to become responsive to LPS. 
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To address this final point in our system, H357 and THP-1 cells were cultured together in a 
trans-well apparatus: H357 cells were grown on a culture insert and macrophages were 
grown in the well plate allowing cell-cell cross talk during the polarisation stage. Hagemann 
et al (2005) reported that co culture with macrophages modulated the behaviour of cancer 
cells and activated inflammatory JNK and NF-κB pathways via TNFα, which in turn lead to 
increased tumour invasiveness140. In the present study, co culture with macrophages did not 
affect the H537 cytokine response to P. gingivalis LPS. The effects of co culture on H357 
invasiveness was not tested, but presents an avenue for investigation in the future. The 
present study focused on the effects of H357 produced soluble factors on macrophage 
responses to P. gingivalis. 
When THP-1 cells were polarised in the presence of H357 cell conditioned media, 
macrophage production of IL-1β and IL-6 was amplified in response to P. gingivalis LPS 
compared to THP-1 cells polarised in their normal media. This pattern of amplification was 
seen across the phenotypes (PMA, M1 and M2). In line with these results, a study by Caras 
et al, used conditioned media from colorectal cancer cell supernatants to polarise PMA 
treated THP-1, and found that they up-regulated  TNFα, IL-6  and IL-1Ra production, 
generating a macrophage population with a mixed M1/M2 phenotype151. When the 
experiment was repeated with an adenocarcinoma cell line, they found the same up 
regulation of TNFα, but not of IL-6 or IL-1Ra. Another study shows that in renal cell 
carcinoma, TAMs have a higher basal level of IL-6, IL-1β and TNFα but respond less 
vigorously to LPS challenge293. The present study indicated the opposite; that conditioned 
media had no effect on TNFα production, and a greatly amplified IL-6. IL-1Ra however was 
not measured. Interestingly, the Caras study, and study by Stewart et al 294, which used 
breast cancer cell line supernatants that up-regulated TNFα, IL-6, RANTES and MCP-1 
production, did not use LPS to stimulate the macrophages; the up regulation in cytokine 
production in the cells was due to factors in the conditioned media only. In the present study, 
it was only IL-6 that was up-regulated  without the need for stimulation by LPS. This 
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suggests that different cancers manipulate local macrophages in ways specific to that 
tumour.  
In the present study, cross talk between the THP-1 and H357 cells made no difference to the 
response of either cell type to P. gingivalis LPS. In contrast, Hagemann et al (2006) showed 
that effects on macrophage polarisation by epithelial cells differed when macrophages were 
exposed to SCC soluble factors via indirect co-culture or conditioned media286. During co-
culture, TNFα, IL-1β and IL-10 (along with other cytokines) were increased. The un-
stimulated epithelial cells did not express TNFα, IL-10, IL-12 and IL-1β, as concurrent with 
the present study.  
To investigate whether the amplification of cytokine production was specific to P. gingivalis, 
the experiments were repeated using E. coli LPS. The same pattern of cytokine amplification 
was seen in response to E. coli LPS as to P. gingivalis LPS, in fact, the amplification was 
greater.  E. coli LPS promotes a more vigorous response than P. gingivalis LPS197, as 
described in previous chapters.  
Pro-inflammatory cytokine expression by H357 cells had not, until now, been characterised. 
In this study, H357 cells did not produce TNFα or IL-1β, but did produce constitutively high 
levels of IL-6. IL-6 can be either inflammatory or anti-inflammatory, depending on its mode of 
signalling (reviewed in 295) and the cell type it elicits its effects on. It can induce the 
production of soluble TNF receptor p55 and IL-1Ra 296, and inhibit TNFα and IL-1β  
production in mononucleocytes297. On the other hand, IL-6 has been shown to increase 
proliferation, cell growth and inhibit apoptosis in squamous cell carcinoma cell lines 298,299 . 
Thus, inducing local macrophages to produce IL-6, as seen in these results, works in favour 
of the tumour. 
Given the evidence supporting the infiltration of anti-inflammatory M2 macrophages in OSCC, 
and the immunosuppressive nature of tumours in general, it seems unusual for pro-
inflammatory cytokines to be up-regulated in macrophages in the present study. 
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Nevertheless, inflammatory cytokines in the tumour microenvironment can play a role in the 
pathological process of cancer; TNFα  has been shown to up regulate  E selectin in 
endothelial cells, thus facilitating metastasis 299–301, and IL-1β acts in an autocrine manner to 
up-regulate TNFα production in SCC 302.   IL-6 plays a pluripotent and complicated role in 
cancer, and has both inflammatory/anti tumoural and anti-inflammatory/pro- tumoural effects. 
It remains to be clarified whether anti-inflammatory cytokines are affected by H357 
conditioned media. Whilst there were lower levels of inflammatory cytokines in the primary 
OSCC samples than the control samples, the conditioned media from both primary and 
H357 cell lines up-regulated inflammatory cytokine production in response to LPS. A 
previous study reported that levels of salivary IL-6 and IL-1β are detected in OSCC patients 
vs. control patients, but TNFα was not elevated303. The cytokines amplified by OSCC 
conditioned media are the same cytokines found in elevated levels in OSCC patient saliva.  
To confirm whether H357 cells behaved like OSCC in vivo, MØ and M2 macrophages were 
polarised in the presence of primary human OSCC conditioned media. In contrast to H357, 
conditioned media, OSCC conditioned media-polarised macrophages exhibited amplified 
TNFα production. However, this did not reach statistical significance.  This may have been 
down to the inter-patient variability of the clinical samples, and the low number of 
experimental replicates (n=3). Furthermore, a difference in response to primary samples 
versus cell lines may arise from the fact that primary samples are not a homogenous 
population of cells, and are likely to contain a multitude of cell types. Therefore, the H357 
cell line makes a viable model for studying cell specific interactions. As seen in the H357 
conditioned media experiments, there was no change in TNFα production in the M1 
macrophages polarised with OSCC conditioned media in response to P. gingivalis  LPS 
compared with M1 macrophages polarised in normal growth medium (Figure  5-12).  
Finally, we sought to determine if OSCC produced factors that may module macrophage 
behaviour. Primary samples of OSCC and excised gingival mucosa (from routine wisdom 
tooth extractions) were cultured for 48 hours and the supernatants were analysed for an 
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array of cytokines. Whilst OSCC tissues expressed most of the cytokines assayed for, 
almost all (bar IL-5) were expressed more highly in the control tissues.  Neither control tissue 
nor tumour tissue produced any TNFα, but did produce IL-6, reflecting the behaviour of the 
H357 cells.  In contrast to previous studies, IL-1β, IL-6 and TGF-β expression was lower 
than in control samples52,304. This discrepancy may be down to small sample sizes and 
variation between laboratories and culture techniques, or the increased level of pro-
inflammatory cytokines in the control tissue in the present study may be a result of 
inflammation in infected wisdom tooth.  
 
Polarisation with conditioned media generated an unexpected result during viability tests.  
M2 macrophages cultured in conditioned media were increased in cell number compared to 
M2 cultured in R10. Furthermore, M2 increased in cell number to a greater extent than M1. If 
this were the case in vivo, it may be that cancer cells promote the proliferation of M2 cells 
preferentially over M1 cells in an effort to aid tumour survival. Nevertheless, Trypan blue 
exclusion is not the optimal assay for cell enumeration; a more relevant protocol would be to 
use a proliferation assay kit, such a WST-1 to measure proliferation of each macrophage 
subset directly in the wells. It may be that not all the cells were harvested by the enzyme 
detachment and therefore cell count may not be accurate. Still, it is an interesting proposition 
given the association of high numbers of M2 macrophages commonly found in in tumour 
microenvironments. Further investigation to identify factors responsible for M2 proliferation is 
required. H357 cells produce high levels of TGF-β269, which has been shown to induce 
proliferation in macrophages305 
Up-regulation of inflammatory cytokines promotes SCC metastasis. Results from the present 
study reveal that H357 cells up regulate pro-inflammatory cytokine production in surrounding 
macrophages, irrespective of their phenotype, most likely as a mechanism to promote 
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metastasis. The cytokines up-regulated  by polarisation with conditioned media are those 
found to be elevated in OSCC sites. 
In conclusion, this study shows for the first time that: 
1) H357 do not produce TNFα or IL-1β constitutively 
2) H357 produce high levels of IL-6 constitutively 
3) H357 do not respond to P. gingivalis  LPS 
4) H357 and primary OSCC conditioned media amplifies macrophage cytokine 
production in response to P. gingivalis  LPS. 
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Chapter 6 - General discussion 
 
Pathological interactions between oral bacteria and polarised macrophages have been 
implicated in a range of oral and systemic diseases. When monocytes are recruited to sites 
of inflammation, they differentiate into macrophages and polarise within a spectrum of 
activation states32. Depending on the factors they encounter in their microenvironment, 
macrophages can be activated to an inflammatory, M1 phenotype or an anti-inflammatory, 
M2 phenotype170.  Macrophages infiltrate areas of inflammation, such as periodontal 
lesions163,168 and tumours222,280, where aberrant M1 and M2 polarisation has been associated 
with disease development306 . Porphyromonas gingivalis ,  a pathogenic oral bacterium, has 
been identified both in periodontal lesions 69 and oral squamous cell carcinomas119–121. In 
OSCC tissues, macrophages have been shown to polarise to an M2 state222. The 
polarisation state of macrophages in periodontitis is yet to be characterised, but it is likely 
that during the acute phase of inflammation, macrophages take on an M1 phenotype in order 
to eradicate invading pathogens. Later in disease progression, macrophages may switch to 
an M2 phenotype in an attempt to resolve inflammation. Indeed, M1 asscoaitate Th1 cells 
are associated with (early) stable periodontal lesions, while M2 associated Th2 cells are 
associated with progressive lesions 101. Thus, macrophages in a variety of differentiation and 
polarisation states are likely to come into contact with P. gingivalis. The present study set out 
to investigate these interactions with two core aims: 
1) Effects of P. gingivalis LPS on M1 and M2 polarisation, and cytokine response to 
subsequent LPS challenge 
2) Effects of OSCC cell conditioned media on M1 and M2 polarisation, and cytokine 
response to subsequent LPS challenge 
The first step was to develop a model of M1 and M2 macrophage polarisation in vitro using 
THP-1 cells. PMA and vitamin D3 are commonly used to stimulate macrophage 
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differentiation102,190 PMA activates the PKC signalling pathway and is a potent inducer of 
inflammation307,308, whereas Vitamin D3 activates the M2 associated309  PI3K pathway 310 
and exhibits anti-inflammatory properties. It was thus hypothesised that PMA and Vitamin D3 
could be used to generate M1 and M2 macrophages, respectively. However, when this 
method was tested, PMA and Vitamin D3 treated cells did not display typical M1 and M2 
cytokine profiles in response to LPS stimulation. In response to LPS, Vitamin D3 treated 
cells produced markedly higher levels of IL-1β  and IL-6 than PMA treated cells, and only 
marginally less TNFα.  PMA treated cells became strongly adherent to the culture plates (a 
marker of macrophage differentiation) , but Vitamin D3 treated cells remained mostly in 
suspension, indicative of incomplete differentiation. A previous study by Daigneault et al 
(2010) 187  also assessed the ability of PMA and Vitamin D3 to generate macrophages. They 
reached the same conclusion; Vitamin D3 treatment leads to a poorly differentiated 
population of cells. Previous reports indicate that PMA treatment leads to development of 
macrophages with an M2-like phenotype 160. Our results, and others 311 corroborate this: In 
the present study, PMA and IL-4 consistently displayed a similar cytokine profile. It may be 
that in the absence of M1- polarising factors, macrophages will default to an M2 phenotype 
to avoid excessive inflammatory respones. 
 
In light of these findings, a polarisation method was adapted from a previous study by Tjiu et 
al (2009)194. The TH1 and TH2 cytokines IFNγ and IL-4, in addition to PMA, were used to 
further push the macrophages along their respective polarisation pathways. This method of 
polarisation resulted in the stable and reproducible production of signature M1 and M2 
cytokine profiles in response to LPS; IFNγ treatment generated TNFα, IL-1β, IL-6 high/IL-10, 
TGF-β low expressing cells, whereas IL-4 treatment generated TNFα, IL-1β, IL-6 low/IL-10, 
TGF-β high expressing cells. Taken together, these data confirm that using IFNγ and IL-4 
with PMA generates a population of cells better resembling M1 and M2 macrophages than 
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cells treated with PMA or Vitamin D3 alone, and that this is an effective method for 
generating M1 and M2 macrophages in vitro.  
In addition to IFNγ, LPS is commonly used to polarise macrophages to an M1 phenotype. 
LPS is renowned for its stimulation of pro-inflammatory cytokine production in a range of 
cells. Before the present study, research into the effect of LPS on the ability of IFNγ or IL-4 
to polarise macrophages had not been conducted. Furthermore, no studies had polarised 
macrophages using LPS from P. gingivalis. To address this, the newly established model of 
M1 and M2 polarisation described above was used to polarise THP-1 cells in combination 
with P. gingivalis LPS. E. coli LPS, used in previous in polarisation protocols151,312, was 
included as a comparison.  Non-polarised macrophages (PMA only) were used to assess the 
effects of LPS on macrophage polarisation in the absence of IFNγ and IL-4. The addition of 
LPS from P. gingivalis or E. coli during macrophage polarisation resulted in a down-
regulation of pro-inflammatory cytokine production in response to a subsequent challenge 
with LPS, even in the presence of IFNγ. This raises an interesting point; using LPS along 
with IFNγ to generate M1 macrophages may be dampening the M1 pro-inflammatory 
cytokine response, rendering the macrophages less M1-like than when polarised with IFNγ 
alone. Moreover, LPS in combination with immune complexes or IL-1β polarises 
macrophages to an M2b phenotype313. If immune complexes/IL-1β are present in 
macrophage environment, this may affect the direction of polarisation. Thus, data from the 
present study suggests that the addition of LPS during polarisation may not be the most 
effective method of generating M1 macrophages.  
One explanation for the decreased cytokine production may be that TLR2 and TLR4 are 
down-regulated in response to LPS. In the present study, MØ and M1 macrophage TLR 
expression decreased following polarisation with P. gingivalis , in contrast to a previous 
study showing that TLR2 expression was up-regulated on THP-1 cells after 24 hours 
incubation with P. gingivalis LPS208. Here however, TLR expression levels were increased in 
the M2 cells, with a concurrent down-regulation of cytokine production.  This indicates that 
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there is another mechanism at play for the down-regulation of cytokines. Nevertheless, 
difference in levels of TLR modulated by P. gingivalis did not reach statistical significance, 
probably due to variance between samples. Therefore, further replications of the experiment 
are needed to confirm these findings. 
In vivo, reduction of pro-inflammatory cytokine expression by macrophages in response to 
prolonged or repeated exposure to LPS may have either beneficial or detrimental effects in 
oral health and pathology. In the early stages of OSCC development for example, a pro-
inflammatory environment might be benefit the host and promote an anti-tumour response. 
However, at later stages of disease, pro-inflammatory cytokines such as TNFα, IL-1β, IL-6 
may benefit tumour progression and facilitate metastasis. In normal mucosal tissues, down-
regulation of cytokine production in response to repeated exposure to LPS is a mechanism 
employed by macrophages and dendritic cells to avoid over-zealous inflammation that would 
result in tissue damage – a phenomenon known as endotoxin tolerance. Several studies 
have assessed mechanisms of endotoxin tolerance in response to P. gingivalis LPS, 
however, each study reported different results regarding the ability of P. gingivalis  to induce 
a tolerogenic state234,254,314,315.  This may be born from several differences in protocols; cell 
treatments, cell types and LPS structures differed between all the experiments.  
Another explanation for the down-regulation of pro-inflammatory cytokines is that LPS is 
skewing the macrophages polarisation to an M2-like phenotype. It has in fact been argued 
that endotoxin tolerised cells exhibit an M2 profile316  Porphyromonas  gingivalis has been 
shown to activate the PI3K pathway203,317 associated with alternative macrophage 
polarisation 189 and negative regulation of M1 markers200,201, up-regulate expression of both 
tolerance252 and M2 associated molecules244,318 and  negative regulator of TLR signalling, 
IRAK-M245. These anti-inflammatory mechanisms exhibited by P. gingivalis LPS potentially 
explain the cytokine down-regulation seen in the present study. The effects of P. gingivalis 
LPS on expression of other negative regulators of TLR signalling, such as PPARγ, TOLLIP, 
SHIP are yet to be investigated and provide an interesting avenue for further investigation 
139 
 
In the present study, a lower concentration of E. coli LPS was able to down regulate cytokine 
production in response to cross stimulation with different LPS, than P. gingivalis LPS. Whilst 
the present study did not directly address the question of endotoxin tolerance, the results 
would suggest that E. coli LPS more effectively down-regulates cytokine production than P. 
gingivalis LPS, in line with previously published data234 Therefore, it is surprising that these 
M2-associated, regulatory mechanisms are up-regulated more strongly by P. gingivalis LPS 
than E. coli LPS245, as  E. coli down-regulates cytokine production to a greater extent than P. 
gingivalis .  Furthermore, pro-inflammatory cytokine production was also down-regulated in 
M2 macrophages, albeit in a different way to M1. Taken together, these data suggest that 
down-regulation of cytokine production is likely due to endotoxin tolerance rather than M2 
skewing. 
Further investigation is needed to assess the levels of tolerance and M2 characteristic 
markers induced by polarisation with P. gingivalis , as the present study only measured 
effects on pro-inflammatory cytokine production.  Whilst previous studies have been 
conducted into the mechanisms of endotoxin tolerance in macrophages, none so far have 
investigated the mechanisms of tolerance in M2, if indeed they can be tolerised at all. Thus, 
this is the first time that a potential tolerogenic mechanism has been described in M2 
macrophages.  
Whilst polarisation in the presence of LPS down-regulates cytokine production in response 
to secondary stimulus with LPS, polarisation with OSCC supernatants results in the exact 
opposite effect.  Polarisation of macrophages in the presence of OSCC cell conditioned 
media led to the amplification of M1- associated cytokine production in response to LPS. 
This is surprising, given that OSCC TAMs have been shown to take on an M2-like profile222. 
Furthermore, it has been demonstrated that TGF-β, produced in high levels in H357 269, up-
regulates expression of negative regulator of TLR signalling, IRAK-M.319 
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There is no consensus on whether P. gingivalis LPS signals through TLR2 or TLR4. 
Porphyromonas gingivalis LPS has been shown to signal via TLR296,203,230–235, a TLR1/2 
heterodimer in concert with CD14 and LBP234,237,  TLR491,209,238–240, TLR2 and TLR7242 or 
both TLR2 and TLR4243. LPS purification methods have been suggested as a reason for this 
discrepancy, with contaminating proteins utilising other TLRs95. Furthermore, bacterial 
viability is thought to account for some of these discrepancies, as purified P. gingivalis LPS 
signals through TLR2 , but live P. gingivalis signals through both TLR2 and TLR4241. In the 
present study, this was investigated using blocking antibodies to TLR2 and TLR4. For TNFα 
and IL-1β  production in  M1 polarised macrophages, P. gingivalis LPS required TLR2.. For 
IL-6 production however, M1 macrophages could utilise TLR2 and TLR4. These data 
suggest that in the present model, P. gingivalis LPS predominantly uses TLR2 to induce 
inflammatory cytokine production, with the exception of IL-6, which can be induced by both 
TLR2 and 4. Whether this is down to the purification method or lipid A structure remains to 
be elucidated. 
Primary OSSC samples and non-cancerous gingival mucosal samples (control) were 
screened for an array of cytokines: IL-10, TGF-β, TNFα, IL-15, IL-6 and IL-8. It must be born 
in mind that primary tissue samples contain a mixed population of cells, some of which may 
have produced the cytokines measured in the supernatants. Because of this, H357 provide a 
good model for investigating cell-specific interactions. 
Whilst all of the cytokines were expressed in both tumour and control tissues, only IL-15 was 
expressed at higher levels in the tumour samples than the control samples; all the rest were 
expressed at higher levels in the control tissue. TNFα was not expressed by either sample, 
reflecting the behaviour of the H357 cells. TNFα has anti-tumour properties, including 
induction of apoptosis. It may be that tumour cells down-regulate TNFα production in order 
to promote survival. However, there was no production of TNFα in the control samples either, 
suggesting that epithelial cells in general do not produce TNFα.  
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The cytokines produced by OSCC samples may have differing effects on the local 
macrophages. IL-10 and TGF-β have been shown to polarise macrophages to an M2 
phenotype 320. Tumour samples produced both of these M2 polarising factors, yet in 
response to conditioned media, macrophages up-regulated production of M1 associated 
cytokines. IL-10 and TGF-β were produced at higher levels in control samples than tumour 
samples. It may be that in the case of OSCC, a less immunosuppressive environment is 
beneficial to the tumour. 
IL-15 is a T cell growth factor, similar to IL-2, that was discovered independently by two 
different groups 321,322. It stimulates B cell immunoglobulin synthesis, cellular proliferation 
and  the generation of cytotoxic T cells,  and NK cells323. IL-15 has little effect on regulatory 
T cells however 324, suggesting an anti-tumour role for this cytokine. Macrophages express 
the IL-15 receptor, 325 and in response to its ligation, they increase phagocytic activity and 
up-regulate IL-12, MCP-1 IL-6, IL-8 and TNFα expression326,327, thus making IL-15 a 
potential candidate for causing the cytokine amplification seen in the present study. 
Although typically thought of as a pro- inflammatory cytokine, IL-6 can exhibit anti-
inflammatory, pro-tumoural effects 295, such as induction of  soluble TNF receptor p55 and 
IL-1Ra production 296, and inhibition of TNFα and IL-1β  production in mononucleocytes 297. 
IL-6 has also been shown to increase proliferation, cell growth and inhibition of apoptosis in 
squamous cell carcinoma cell lines 298,299 , and has been implicated in tumour multi-drug 
resistance328. Thus, the high constitutive levels of IL-6 production by OSCC cells with a 
concomitant up-regulation of IL-6 in macrophages may be an attempt by the tumour to 
promote an environment permissive to its survival. The role of IL-6 in the amplification of 
macrophage cytokine production provides and promising target for further investigations into 
the mechanisms of this phenomenon. A full screening of H357 supernatants is needed to 
identify other targets for further investigation. 
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One such potential target for investigation is IL-17. Recent studies have implicated IL-17 in 
OSCC; IL-17 and its receptors are present at higher levels in PMNs and PBMCs from OSCC 
patients than control, and Foxp3+ IL-17+ CD4+ T cells infiltrate OSCC tumours50,329. 
Furthermore, it has been shown to up-regulate TNFα and IL-1β  in macrophages 330,331, and 
IL-6 and IL-8 in gingival fibroblasts 331,332 and rheumatoid synovial cells 333. Macrophages 
express IL-17 receptor  334, thus it can be hypothesised that if IL-17 is present in the 
conditioned media, it could be responsible for the cytokine amplification seen in the present 
study.  
Manipulation of macrophage function in pathological scenarios is as potential target for 
therapy. Tumour produced factors influence the effector functions of macrophages in the 
microenvironment. As such, is serves that if tumour cytokine expression can be modulated, 
this in turn could modulate macrophage function. The cell line H357 has been used  to 
investigate pathological mechanisms in OSCC 263–265, but the response of these cells to P. 
gingivalis has not been investigated.  Since OSCC cells and P. gingivalis are likely to come 
into contact in vivo, a study was designed to assess the cytokine response of H357 to P. 
gingivalis: LPS.  
First, to assess whether H357 had the capacity to respond to LPS, the expression of LPS 
receptors TLR2 and TLR4 were measured on the cell surface by FC. H357 cells were 
positive for both TLR2 and TLR4, although there was no significant difference in expression 
between the TLRs. In line with the current findings, human gingival epithelial cells have also 
been shown to express TLR2 and 4 289–291, hence loss of TLR expression does not appear to 
be affected by cancerous transformation in the H357 cells.  Secondly, after the expression of 
LPS receptors was confirmed, cytokine production in response to P. gingivalis  LPS was 
addressed. In accordance with previously published data215,286, there was no TNFα or IL-1β 
production in the H357 cells, either constitutively or in response to LPS. IL-6 was produced 
constitutively, as reported in  previous studies on squamous cell carcinoma cell lines286,288,. 
TNFα, IL-1β and IL-6 production was not affected by the addition of LPS, despite the 
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expression of LPS receptors on the cell surface. However, it remains to be confirmed 
whether H357 cells express LPS co-receptor CD14, or the intracellular signalling pathways 
that lead to cytokine production.  
 In contrast to the current findings, other studies have shown that primary gingival epithelial 
cells do produce IL-8, MCP-1, TNFα and IL-1β in response to  P. gingivalis LPS 271,287. 
Therefore, it remains to be confirmed whether oral epithelial cells produce cytokines in 
response to bacterial challenge. Data from the present study shows that H357 cells, at least, 
do not respond to P. gingivalis LPS.  
Hagemann et al (2006) 286 showed that SCC cytokine expression was increased when 
macrophages were polarised by exposure to SCC soluble factors in a trans-well set up, but 
not in response to exposure via conditioned media286, indicating that macrophage/SCC cross 
talk was vital for cytokine up-regulation by SCC cells. In the present study however, trans-
well co-culture had no effect on cytokine production in the H357 cells, suggesting that LPS 
un-responsiveness is a characteristic specific to these OSCC cells. 
Future directions and Closing remarks  
Given the pro-inflammatory and anti-inflammatory properties of LPS and tumour cell 
produced factors (respectively), it could be speculated that LPS polarising would up-regulate 
pro-inflammatory cytokine production, and tumour conditioned media polarising would down 
regulate pro-inflammatory cytokine production. Surprisingly, the opposite was true. It could 
be that in both cases, the immune system is working to overcome its respective challenges – 
down-regulation of cytokines in response to repeated LPS exposure to limit tissue damage 
and resolve inflammation, and up-regulation of inflammatory cytokines in response to tumour 
secreted factors in an attempt to drive the adaptive response to an anti tumoural one. In the 
first instance, it would be necessary to identify what in the OSCC conditioned media is 
promoting this effect by screening for a wide array of potential candidates. As IL-6 is 
produced in copious amounts, this would be a logical place to start. Given that the presence 
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of LPS or conditioned media during polarisation have opposing effects on macrophage 
responses to LPS, it would be of interest to examine whether OSCC conditioned media can 
override the tolerance-like down-regulation of cytokine production seen in response to LPS 
polarisation.  
Data from the present study confirms that macrophages express TLR2 and TLR4 as 
reported in the literature335. Previous research has suggested that factors produced by 
carcinomas can activate myeloid cells via TLR2, stimulating metastasis 336 Furthermore, 
Lewis lung cell carcinoma supernatants induce IL-6 and TNFα production from macrophages 
via TLR- 2 and -6 336. Therefore, it could be hypothesised that factors produced by OSCC 
cells might activate macrophages via TLR pathways, resulting in the amplification of pro-
inflammatory cytokines reported in this study. The effects of blocking TLR2 and TLR4 
signalling in macrophages before the addition of OSCC conditioned media may prove an 
interesting avenue of investigation.  
Based on the evidence from the present study, is not possible to determine whether the 
H357 cells are acting like normal epithelial cells or are more representative of oral squamous 
cell carcinoma cells. It has previously been reported that cancer cell lines grown as a 
monolayer do not truly replicate their behaviour in vivo and behave more like tumours if they 
are grown in 3-dimentional culture as tumour spheres 337–339. In fact, tumour cells grown in 
spheroids have been shown to modulate macrophage polarisation differentially from cells 
grown in a monolayer337. These multi layered structures more accurately reproduce the 
tumour microenvironment, including development an anoxic core. Given that P. gingivalis 
has been isolated from OSCC cores119, this provides an ideal model for the investigation of 
bacteria/tumour/macrophage interactions. Preliminary experiments in this lab show that 
H357 cells readily form spheroids (data not shown). 
An unexpected result was revealed during viability tests after polarisation with conditioned 
media: M2 macrophages cultured in conditioned media had increased in cell number 
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compared to M2 cultured in R10. Furthermore, M2 increased in cell number to a greater 
extent than M1. However, a more accurate method of cell enumeration needs to be 
executed before any conclusions are drawn from these data. Nevertheless, it is tempting to 
hypothesise that cancer cells promote the proliferation of M2 cells preferentially over M1 
cells in an effort to aid tumour survival, especially given the association of high numbers of 
M2 macrophages commonly found in in tumour microenvironments.  Moreover, H357 cells 
produce high levels of TGF-β269, which has been shown to induce proliferation in 
macrophages305. Thus, in light of this preliminary data, a more robust study into the effects of 
OSCC secreted factors on proliferation in M1 and M2 macrophages should be conducted. 
 
In vivo, macrophages and OSCC cells will not only come into contact with P. gingivalis LPS, 
but multitude of other virulence factors. Thus, a limitation of this study is that polarisation 
with and subsequent responses to P. gingivalis were only carried out using its LPS. Indeed, 
it has been shown that membrane associate molecules, such as fimbriae,  have different 
effects on macrophage function compared with LPS340, and that both LPS and fimbriae in 
turn modulate macrophage function in a different way from the live bacterium233,241,340,341. 
Therefore, future investigations should involve the use of live P. gingivalis to address this 
issue.  
 In conclusion, the key findings from the present study report: 
1) Development of a reproducible model of M1 and M2 polarisation using THP-1 cells 
2) Exposure of macrophages to LPS during polarisation leads to a down-regulation of 
inflammatory cytokines in response to subsequent stimulation with LPS 
3) M1 macrophages display higher levels of TLR2 and TLR4 on the cell surface than 
M2, however, this needs further investigation to clarify. 
4) H357 cells express LPS receptors, TLR2 and TLR4 
5) H357 cells do not produce TNFα or IL-1β, either constitutively or in response to LPS 
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6) H357 produce high levels of IL-6 constitutively; this is not affected by the addition of 
LPS 
7) H357 and primary OSCC conditioned media amplify macrophage cytokine production 
in response to P. gingivalis  LPS.  
The findings reported in the present study may have wider reaching implications;  P. 
gingivalis has been associated with the progression of non-orally related diseases, such 
as atherosclerosis217,342–347 and rheumatoid arthritis348–350 (reviewed in 351and 352).  
Therefore, the continued study of macrophage/ P. gingivalis interactions may shed light 
on pathogenic mechanisms not only in oral pathological conditions, but in a range of 
diseases.  
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Appendix 1 
 
TGFβ-1 ELISA Optimisation: antibody concentrations 
 
Antibodies were added to wells in combinations of concentrations as shown below: 
 
Coating antibody: 0.5 µg/ml Detection antibody: 0.5µg/ml 
Coating antibody: 0.5 µg/ml Detection antibody: 1µg/ml 
Coating antibody: 0.5 µg/ml Detection antibody: 2µg/ml 
 
Coating antibody: 1µg/ml Detection antibody: 0.5µg/ml 
Coating antibody: 1 µg/ml Detection antibody: 1µg/ml 
Coating antibody: 1 µg/ml Detection antibody: 2µg/ml 
 
Coating antibody: 2µg/ml Detection antibody: 0.5µg/ml 
Coating antibody: 2µg/ml Detection antibody: 1µg/ml 
Coating antibody: 2µg/ml Detection antibody: 2µg/ml 
 
Coating antibody: 4µg/ml Detection antibody: 0.5µg/ml 
Coating antibody: 4µg/ml Detection antibody: 1µg/ml 
Coating antibody: 4µg/ml Detection antibody: 2µg/ml 
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TGF-β1 ELISA Protocol 
(LAB-January 2009) 
BD Biosciences/Pharmingen paired antibodies 
TGF-β1 coating antibody: (Purified Rat Anti-Mouse, Human, Pig)    cat no: 555052 lot: 49897  
TGF-β1 detection antibody: (Biotin Rat Anti-Mouse, Human, Pig) cat no: 555053 lot: 67324  
NIBSC TGF-β1 standard 89/514:  160ng in 1.6ml R10 = 100 ng/ml, 50µl aliquots   
       
1. Coat 96 well microtitre plate with 50µl per well coating antibody (stock 0.5mg/ml)@ 
4µg/m in PBS. Leave O/N at 4oC. 
2. Wash x3 with PBS/0.05%-Tween20 ELISA wash buffer. 
3. Block with 150µl per well 2% BSA/PBS for 4 hours @ room temperature. 
4. Wash x3 with PBS/0.05%-Tween20 ELISA wash buffer. 
5. Prepare standard curve: Top concentration 5000pg/ml, then 1 in 3 dilutions (5000-
7pg/ml). 
6. Add standards and test samples 50µl per well. Leave O/N at 4oC. 
7. Wash x3 with PBS/0.05%-Tween20 ELISA wash buffer. 
8. Add 50µl per well detection antibody (stock 0.5mg/ml) @ 2µg/ml in PBS/1% BSA. 
Leave 4 hours @ RT. 
9. Wash x3 with PBS/0.05%-Tween20 ELISA wash buffer. 
10.  Add 50µl per well Streptavidin-HRP (conjugate: R&D Systems, DY998 part 890803) 
@ 1/250 dilution in PBS/1% BSA.  Leave at RT for 1 hour.  
11. Wash x3 with PBS/0.05%-Tween20 ELISA wash buffer. 
12.  Add TMB substrate reagent (KPL, cat: 50-76-03) 50µl per well (A:B = 50:50).  
13. Allow colour to develop @ RT. Stop colour reaction with 50µl per well 1.8M H2SO4. 
14. Read absorbance @ 450nm
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Human TGF-β ELISA optimization plate layout 
 
Detection antibody Capture antibody Standard 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
5 ng/ml A 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
1 in 3 
dilutions 
B 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
 C 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
 D 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
 E 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
 F 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
 G 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
0ng/ml H 0.5µg/ml 
0.5µg/ml 
1µg/ml 
0.5µg/ml 
2µg/ml 
0.5µg/ml 
0.5µg/ml 
1.0µg/ml 
1µg/ml 
1.0µg/ml 
2µg/ml 
1.0µg/ml 
0.5µg/ml 
2.0µg/ml 
1µg/ml 
2.0µg/ml 
2µg/ml 
2.0µg/ml 
0.5µg/ml 
4.0µg/ml 
1µg/ml 
4.0µg/ml 
2µg/ml 
4.0µg/ml 
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TGFβ-1 ELISA Optimisation
(log10) TGFβ-1 Standard Concentration (µg/ml)
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1.5
2.0
2.5
Coat 2µg/ml -  detect 0.5µg/ml
Coat 2µg/ml - detect 1µg/ml 
Coat 2µg/ml - detect 2µg/ml 
Coat 4µg/ml - detect 0.5µg/ml 
Coat:4µg/ml - Detect 1µg/ml
Coat 4µg/ml - detect 2µg/ml 
 
Figure  6-1 Plot of TGF-β standard concentrations from chequerboard optimising technique 
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Figure  6-2: Plot of optimal concentrations for TGF-β capture and detect antibodies 
 
  
 
  
TGF-β1 Standard Curve
(log10) TGF-β1 standard concentration (ng/ml)
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Coat Ab: 4µg/ml - detection Ab: 2µg/ml
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